1
|
Ammer‐Herrmenau C, Hamm J, Neesse A. Autoimmune pancreatitis-New evidence for clinical management strategies. United European Gastroenterol J 2024; 12:279-280. [PMID: 38271283 PMCID: PMC11017752 DOI: 10.1002/ueg2.12537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2024] Open
Affiliation(s)
- C. Ammer‐Herrmenau
- Department of Gastroenterology, Gastrointestinal Oncology and EndocrinologyUniversity Medical Center GoettingenGoettingenGermany
| | - J. Hamm
- Department of Gastroenterology, Gastrointestinal Oncology and EndocrinologyUniversity Medical Center GoettingenGoettingenGermany
| | - A. Neesse
- Department of Gastroenterology, Gastrointestinal Oncology and EndocrinologyUniversity Medical Center GoettingenGoettingenGermany
| |
Collapse
|
2
|
Parmar GS, Kong T, Hamm J, Liu M, Lefresne S, Carolan H, Berthelet E, Chan J, Nichol A. RAPid SimPLE (RAPPLE) Targeted Radiation Treatment vs. Whole Brain Radiotherapy: A Retrospective Study of Matched Patients with Brain Metastases and Poor Prognosis. Int J Radiat Oncol Biol Phys 2023; 117:e141. [PMID: 37784714 DOI: 10.1016/j.ijrobp.2023.06.951] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Patients with brain metastases and poor prognosis are often treated with whole brain radiotherapy (WBRT) which can cause a variety of side effects. Our institution devised a new brain-sparing radiotherapy technique to treat multiple brain metastasis for patients whose poor prognosis does not warrant SRS. This study compares the oncologic outcomes of matched patients treated with RAPPLE and WBRT. MATERIALS/METHODS RAPPLE uses single-isocenter, coplanar volumetric modulated arc therapy and a non-stereotactic head-shell with IntegraBite™. Brain metastasis were contoured in a single gross tumor volume and expanded by 3 mm to create a planning target volume, of which 99.5% was covered with 95-110% of 20 Gy in 5 fractions. Patients treated with a first course of RAPPLE from January 2017 to December 2021 were identified in an institutional database. Using age, cancer diagnosis, and treatment date, we identified a matched cohort of patients receiving a first course of WBRT with 20 Gy in 5 fractions. Overall survival (OS) was calculated using the Kaplan-Meier method, and intracranial progression was calculated using cumulative incidence with a competing risk of death. Log-rank, Cox regression and Fine-Gray analyses were used for comparisons. Paired t-tests were used to compare patient-reported fatigue measured using 5-level Likert scales before and 2-6 weeks after radiotherapy. RESULTS The RAPPLE and WBRT cohorts each had 137 patients. The matched median age was 69 years. Primary diagnoses were lung cancer (72%) and other cancers (28%). The minimum, median, and maximum numbers of metastases treated with RAPPLE were 1, 3, and 18, respectively. The median Karnofsky Performance Score (KPS) was 70 in both cohorts. The median survival was 4.1 months for RAPPLE and 4.2 months for WBRT, and the 18-month OS was 11% for RAPPLE and 12% for WBRT (log-rank p = 0.8). On multivariable analysis, KPS, diagnosis, extracranial disease, and use of systemic therapy before and after RT were predictive of OS, but use of RAPPLE vs. WBRT was not (HR = 0.97, 95% CI: 0.75-1.25, p = 0.8). The 18-month cumulative incidence of intracranial progression was 0.49 for RAPPLE and 0.37 for WBRT (p = 0.04). After RAPPLE, 17% required more focal RT and 4% required salvage WBRT, while after WBRT, 3% required focal RT and 4% required repeat WBRT. After RAPPLE, mean patient-reported fatigue remained stable from baseline to first follow-up (2.18 vs. 2.27, p = 0.9), but, after WBRT, it worsened from baseline to first follow-up (1.95 vs. 2.63, p = 0.002). CONCLUSION As expected, after RAPPLE, more targeted radiotherapy was required for intracranial progression, but there was no difference in OS between the RAPPLE and WBRT cohorts. Patients reported significantly worse fatigue after WBRT. Almost all patients (96%) treated with RAPPLE avoided WBRT.
Collapse
Affiliation(s)
- G S Parmar
- BC Cancer, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada
| | - T Kong
- University of British Columbia, Vancouver, BC, Canada; BC Cancer Vancouver, Vancouver, BC, Canada
| | - J Hamm
- BC Cancer, Vancouver, BC, Canada
| | - M Liu
- BC Cancer, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada
| | - S Lefresne
- University of British Columbia, Vancouver, BC, Canada; BC Cancer Vancouver, Vancouver, BC, Canada
| | - H Carolan
- BC Cancer, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada
| | - E Berthelet
- BC Cancer, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada
| | - J Chan
- BC Cancer, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada
| | - A Nichol
- BC Cancer, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada
| |
Collapse
|
3
|
Dangelo A, Arbour G, Koulis T, Hamm J, Speers C, Yurkowski E, Matlock S, Stedford A, Tyldesley S, Lohrisch C, Nichol A, Olson R. Impact of Quality Assurance and Feedback on Radiotherapy Prescribing Practices: A Randomized Controlled Trial. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
4
|
Koppe U, Spurgat C, knoop JM, Hahne A, Appenroth MN, Pöge K, Hamm J. Up to the TASG: a participatory study on sexual health of trans and non-binary persons in Germany. Eur J Public Health 2022. [DOI: 10.1093/eurpub/ckac131.506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Problem
Comprehensive data on the sexual health of trans and non-binary people are not available due to lacking focus on these groups and inappropriate study designs that often fail to capture the lived realities of these communities.
Description of the practice
A participatory study was developed with trans and non-binary representatives with a qualitative part involving single and group interviews as well as the development and roll-out of a quantitative online questionnaire. After securing funding, we started the study in 2020 ensuring community involvement in as many parts as possible.
Results
A crucial component is the advisory board including people representing a broad spectrum of trans and non-binary communities, organizations, who are also representing a variety of intersectional perspectives, e.g. BIPoC and neurodiverse people. The advisory board provides crucial input to the design and conduct of the study components. For the qualitative part, a unique study design was developed using sexual health & empowerment workshops for trans and non-binary people in a trustful peer setting combined with qualitative data collection. This way, participants of the study truly benefit from participation and the data quality is improved. The quantitative study was created together with >20 community representatives. Items on gender identity, transition, and experiences of discrimination were developed using online workshops and written feedback. The questionnaire was checked by community members to ensure appropriate language. Through diverse community channels and social media, we recruited 58 participants for the qualitative part and more than 2000 participants for the online questionnaire. The results are expected in late 2022.
Lessons
Involvement of community representatives and the participatory study design ensured strong community support. This enables the capture of meaningful information on the sexual health of trans and non-binary people.
Key messages
• Using a participatory study design was crucial to the success of this study.
• We were able to conduct a study capturing meaningful data on the sexual health of trans and non-binary communities.
Collapse
Affiliation(s)
- U Koppe
- Department of Infectious Disease Epidemiology, Robert Koch Institute , Berlin, Germany
| | | | | | | | - MN Appenroth
- Institute of Public Health, Charité Universitätsmedizin Berlin , Berlin, Germany
| | - K Pöge
- Department of Infectious Disease Epidemiology, Robert Koch Institute , Berlin, Germany
| | - J Hamm
- Deutsche Aidshilfe, Berlin, Germany
| |
Collapse
|
5
|
Warehime J, Lenger S, Cope Z, Feroz R, Gupta A, Francis S, Hamm J. Watching surgical tapes: video playback as an educational tool for improving resident laparoscopic performance. Am J Obstet Gynecol 2022. [DOI: 10.1016/j.ajog.2021.12.158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
6
|
Zhou C, Das Thakur M, Srivastava M, Zou W, Xu H, Ballinger M, Felip E, Wakelee H, Altorki N, Reck M, Liersch R, Kryzhanivska A, Harada M, Tanaka H, Hamm J, McCune S, McNally V, Bennett E, Gitlitz B, Novello S. 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.018] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
7
|
Kim M, Narinesingh D, Hamm J, Marwaha A, Zhao R, Malyala R, Proulx R, Jaswal J, Karvat A, Leong C, Krauze A. Radiation Therapy in Elderly Patients With Squamous Cell Carcinoma of the Head and Neck — Insights From Real World Registry DATA (2007-2017). Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
8
|
Oh J, Tyldesley S, Pai H, McKenzie M, Halperin R, Duncan G, Morton G, Keyes M, Hamm J, Morris W. An Updated Analysis of Survival Endpoints for ASCENDE-RT, a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2194] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Ann Oncol 2019; 29:1995-2002. [PMID: 30084934 DOI: 10.1093/annonc/mdy253] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
Background Treatment options for soft tissue sarcoma (STS) patients aged ≥65 years (elderly) can be limited by concerns regarding the increased risk of toxicity associated with standard systemic therapies. Trabectedin has demonstrated improved disease control in a phase III trial (ET743-SAR-3007) of patients with advanced liposarcoma or leiomyosarcoma after failure of anthracycline-based chemotherapy. Since previous retrospective analyses have suggested that trabectedin has similar safety and efficacy outcomes regardless of patient age, we carried out a subgroup analysis of the safety and efficacy observed in elderly patients enrolled in this trial. Patients and methods Patients were randomized 2 : 1 to trabectedin (n = 384) or dacarbazine (n = 193) administered intravenously every-3-weeks. The primary end point was overall survival (OS); secondary end points were progression-free survival (PFS), time-to-progression, objective response rate (ORR), duration of response, symptom severity, and safety. A post hoc analysis was conducted in the elderly patient subgroup. Results Among 131 (trabectedin = 94; dacarbazine = 37) elderly patients, disease characteristics were well-balanced and consistent with those of the total study population. Treatment exposure was longer in patients treated with trabectedin versus dacarbazine (median four versus two cycles, respectively), with a significantly higher proportion receiving prolonged therapy (≥6 cycles) in the trabectedin arm (43% versus 23%, respectively; P = 0.04). Elderly patients treated with trabectedin showed significantly improved PFS [4.9 versus 1.5 months, respectively; hazard ratio (HR)=0.40; P = 0.0002] but no statistically significant improvement in OS (15.1 versus 8.0 months, respectively; HR = 0.72; P = 0.18) or ORR (9% versus 3%, respectively; P = 0.43). The safety profile for elderly trabectedin-treated patients was comparable to that of the overall trabectedin-treated study population. Conclusions This subgroup analysis of the elderly population of ET743-SAR-3007 suggests that elderly patients with STS and good performance status can expect clinical benefit from trabectedin similar to that observed in younger patients. Trial registration www.clinicaltrials.gov, NCT01343277.
Collapse
Affiliation(s)
- R L Jones
- Seattle Cancer Care Alliance, Seattle
| | - G D Demetri
- Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Ludwig Center at Harvard, Boston
| | | | - M Milhem
- University of Iowa Hospitals and Clinics, Iowa City
| | - A Elias
- University of Colorado Cancer Center, Aurora
| | - B A Van Tine
- Division of Oncology, Washington University in St. Louis, St. Louis
| | - J Hamm
- Norton Cancer Institute, Louisville
| | - S McCarthy
- Clinical Oncology, Janssen Research and Development, Raritan
| | - G Wang
- Clinical Biostatistics, Janssen Research and Development, Raritan
| | - T Parekh
- Clinical Oncology, Janssen Research and Development, Raritan
| | - R Knoblauch
- Clinical Oncology, Janssen Research and Development, Raritan
| | - M L Hensley
- Memorial Sloan Kettering Cancer Center, New York
| | - R G Maki
- Monter Cancer Center, Northwell Health, Lake Success; Cold Spring Harbor Laboratory, Cold Spring Harbor
| | - S Patel
- Department of Sarcoma Medical Oncology, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston
| | - M von Mehren
- Department of Hematology and Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA.
| |
Collapse
|
10
|
Wong S, Hamm J, Shokoohi A, Mcgahan C, Ho C. Curative treatment timelines for breast, colorectal, lung and prostate cancer: Implications for medical leave coverage. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz263.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
11
|
Weiss JM, Csoszi T, Maglakelidze M, Hoyer RJ, Beck JT, Domine Gomez M, Lowczak A, Aljumaily R, Rocha Lima CM, Boccia RV, Hanna W, Nikolinakos P, Chiu VK, Owonikoko TK, Schuster SR, Hussein MA, Richards DA, Sawrycki P, Bulat I, Hamm JT, Hart LL, Adler S, Antal JM, Lai AY, Sorrentino JA, Yang Z, Malik RK, Morris SR, Roberts PJ, Dragnev KH. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol 2019; 30:1613-1621. [PMID: 31504118 PMCID: PMC6857609 DOI: 10.1093/annonc/mdz278] [Citation(s) in RCA: 94] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6 inhibitor in development to proactively preserve HSPC and immune system function during chemotherapy (myelopreservation). Preclinically, trilaciclib transiently maintains HSPC in G1 arrest and protects them from chemotherapy damage, leading to faster hematopoietic recovery and enhanced antitumor immunity. PATIENTS AND METHODS This was a phase Ib (open-label, dose-finding) and phase II (randomized, double-blind placebo-controlled) study of the safety, efficacy and PK of trilaciclib in combination with etoposide/carboplatin (E/P) therapy for treatment-naive extensive-stage small-cell lung cancer patients. Patients received trilaciclib or placebo before E/P on days 1-3 of each cycle. Select end points were prespecified to assess the effect of trilaciclib on myelosuppression and antitumor efficacy. RESULTS A total of 122 patients were enrolled, with 19 patients in part 1 and 75 patients in part 2 receiving study drug. Improvements were seen with trilaciclib in neutrophil, RBC (red blood cell) and lymphocyte measures. Safety on trilaciclib+E/P was improved with fewer ≥G3 adverse events (AEs) in trilaciclib (50%) versus placebo (83.8%), primarily due to less hematological toxicity. No trilaciclib-related ≥G3 AEs occurred. Antitumor efficacy assessment for trilaciclib versus placebo, respectively, showed: ORR (66.7% versus 56.8%, P = 0.3831); median PFS [6.2 versus 5.0 m; hazard ratio (HR) 0.71; P = 0.1695]; and OS (10.9 versus 10.6 m; HR 0.87; P = 0.6107). CONCLUSION Trilaciclib demonstrated an improvement in the patient's tolerability of chemotherapy as shown by myelopreservation across multiple hematopoietic lineages resulting in fewer supportive care interventions and dose reductions, improved safety profile, and no detriment to antitumor efficacy. These data demonstrate strong proof-of-concept for trilaciclib's myelopreservation benefits. CLINICAL TRAIL NUMBER NCT02499770.
Collapse
Affiliation(s)
- J M Weiss
- Division of Hematology and Oncology, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, USA
| | - T Csoszi
- Oncology, Hetenyi Geza Korhaz, Onkologiai Kozpont, Szolnok, Hungary
| | - M Maglakelidze
- Department of Oncology, Research Institute of Clinical Medicine, Tbilisi, Georgia, USA
| | - R J Hoyer
- Department of Oncology, Memorial Hospital, University of Colorado Health, Colorado Springs, USA
| | - J T Beck
- Department of Medical Oncology and Hematology, Highlands Oncology Group, Fayetteville, USA
| | - M Domine Gomez
- Department of Oncology, University Hospital Fundacion Jimenez Diaz, IIS-FJD, Madrid, Spain
| | - A Lowczak
- Department of Pulmonology, Faculty of Health and Science, University of Warmia and Mazury in Olsztyn, Poland
| | - R Aljumaily
- Stephenson Cancer Center, University of Oklahoma, Oklahoma City, USA
| | - C M Rocha Lima
- Gibbs Cancer Center and Research Institute, Spartanburg, USA
| | - R V Boccia
- Center for Cancer and Blood Disorders, Bethesda, USA
| | - W Hanna
- Hematology/Oncology, University of Tennessee Medical Center, Knoxville, USA
| | - P Nikolinakos
- University Cancer & Blood Center, LLC, Athens, Greece
| | - V K Chiu
- Department of Hematology/Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, USA
| | - T K Owonikoko
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, USA
| | | | - M A Hussein
- Department of Oncology, Florida Cancer Specialists, Leesburg, USA
| | - D A Richards
- Department of Oncology, US Oncology Research, Tyler, USA
| | - P Sawrycki
- Department of Cancer Chemotherapy, Provincial Hospital, Toruń, Poland
| | - I Bulat
- ARENSIA Oncology Unit, Institute of Oncology, Chisinau, Moldova
| | - J T Hamm
- Department of Medical Oncology, Norton Health Care, Louisville, USA
| | - L L Hart
- Drug Development Program, Floridia Cancer Specialists, Fort Myers, USA
| | - S Adler
- Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA
| | - J M Antal
- Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA
| | - A Y Lai
- Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA
| | - J A Sorrentino
- Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA
| | - Z Yang
- Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA
| | - R K Malik
- Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA
| | - S R Morris
- Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA
| | - P J Roberts
- Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA
| | - K H Dragnev
- Department of Hematology/Oncology, Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, USA.
| |
Collapse
|
12
|
Tsien C, Pugh S, Dicker A, Raizer J, Matuszak M, Lallana E, Huang J, Algan O, Taylor N, Portelance L, Villano J, Hamm J, Oh K, Ali A, Kim M, Lindhorst S, Mehta M. Randomized Phase II Trial of Re-Irradiation and Concurrent Bevacizumab versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma (NRG Oncology/RTOG 1205): Initial Outcomes and RT Plan Quality Report. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.539] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
13
|
Yeung R, Beaton L, Rackley T, Weber B, Hamm J, Lee R, Camborde M, Pearson M, Duzenli C, Loewen S, Liu M, Ma R, Schellenberg D. Stereotactic Body Radiotherapy for Small Unresectable Hepatocellular Carcinomas. Clin Oncol (R Coll Radiol) 2019; 31:365-373. [DOI: 10.1016/j.clon.2019.01.012] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2018] [Revised: 01/08/2019] [Accepted: 01/08/2019] [Indexed: 12/31/2022]
|
14
|
Dosani M, Yang R, McLay M, Wilson D, Liu M, Yong-Hing CJ, Hamm J, Lund CR, Olson R, Schellenberg D. Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy. ACTA ACUST UNITED AC 2019; 26:e57-e63. [PMID: 30853810 DOI: 10.3747/co.26.4167] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Introduction Stereotactic ablative radiotherapy (sabr) is a relatively new technique for the curative-intent treatment of patients with inoperable early-stage non-small-cell lung cancer (nsclc). Previous studies have demonstrated a prognostic value for positron emission tomography-computed tomography (pet/ct) parameters, including maximal standardized uptake value (suvmax), metabolic tumour volume (mtv), and total lesion glycolysis (tlg) in lung cancer patients. We aimed to determine which pet/ct parameter is most prognostic of local control (lc) and overall survival (os) in patients treated with sabr for nsclc. Methods We conducted a retrospective review of patients treated with sabr for stage I inoperable nsclc at BC Cancer between 2009 and 2013. The Akaike information criterion was used to compare the prognostic value of the various pet/ct parameters. Results The study included 134 patients with a median age of 76 years. Median tumour diameter was 2.2 cm, gross tumour volume was 8.1 mL, suvmax was 7.9, mtv was 2.4 mL, and tlg was 10.9 suv·mL. The 2-year lc was 92%, and os was 66%. On univariate and multivariate analysis, imaging variables including tumour size, gross tumour volume, suvmax, mtv, and tlg were all associated with worse lc. Tumour size was not associated with significantly worse os, but other imaging variables were. The pet/ct parameter most prognostic of lc was mtv. Compared with suvmax, tlg and mtv were more prognostic of os. Conclusions In patients with early-stage nsclc treated with sabr, mtv appears to be prognostic of lc and os.
Collapse
Affiliation(s)
- M Dosani
- Department of Radiation Oncology and Developmental Therapeutics, BC Cancer-Vancouver Centre, and Department of Surgery, Faculty of Medicine, Vancouver, BC
| | - R Yang
- Department of Radiation Oncology and Developmental Therapeutics, BC Cancer-Vancouver Centre, and Department of Surgery, Faculty of Medicine, Vancouver, BC
| | - M McLay
- Department of Radiation Oncology and Developmental Therapeutics, BC Cancer-Centre for the North, and Department of Surgery, Faculty of Medicine, Prince George, BC
| | - D Wilson
- Department of Functional Imaging, BC Cancer-Vancouver Centre, Vancouver, BC
| | - M Liu
- Department of Radiation Oncology and Developmental Therapeutics, BC Cancer-Vancouver Centre, and Department of Surgery, Faculty of Medicine, Vancouver, BC
| | - C J Yong-Hing
- Department of Radiology, BC Cancer-Vancouver Centre, and Department of Radiology, Faculty of Medicine, University of British Columbia, Vancouver, BC
| | - J Hamm
- Cancer Surveillance and Outcomes, BC Cancer, Vancouver, BC
| | - C R Lund
- Department of Radiation Oncology and Developmental Therapeutics, BC Cancer-Fraser Valley Centre, Surrey, and Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, BC
| | - R Olson
- Department of Radiation Oncology and Developmental Therapeutics, BC Cancer-Centre for the North, and Department of Surgery, Faculty of Medicine, Prince George, BC
| | - D Schellenberg
- Department of Radiation Oncology and Developmental Therapeutics, BC Cancer-Fraser Valley Centre, Surrey, and Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, BC
| |
Collapse
|
15
|
Heckhausen J, Hamm J. WORK AND RETIREMENT IN OLD AGE: NORMATIVE PATHS AND INDIVIDUAL AGENCY. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.3211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- J Heckhausen
- University of California-Irvine, Irvine, California
| | - J Hamm
- University of California, Irvine, Irvine, California
| |
Collapse
|
16
|
Hamm J, Heckhausen J, Shane J, Lachman ME. DOES REMAINING EMPLOYED IN MIDLIFE AND OLD AGE PROTECT AGAINST LOSSES IN COGNITIVE FUNCTIONING? A COMPARISON OF MATCHED SAMPLES. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.3212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- J Hamm
- University of California, Irvine, Irvine, California, United States
| | - J Heckhausen
- University of California, Irvine, Irvine, CA, USA
| | - J Shane
- Brooklyn College, The City University of New York, New York, NY, USA
| | | |
Collapse
|
17
|
Jahanzeb M, Gilmore T, Roach A, Grubbs S, Blayney D, Hamm J, Kamal A, Kelly R, Martin E, Sanchez J, Siegel R, Crist S, Rosenthal J, Hendricks C. Can measuring quality lead to improvement? Evidence from international participants of ASCO’s quality oncology practice initiative (QOPI®) during 2015-2017. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy297.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
18
|
Hughes L, Hamm J, McGahan C, Baliski C. Surgeon Volume, Patient Age, and Tumor-Related Factors Influence the Need for Re-Excision After Breast-Conserving Surgery. Ann Surg Oncol 2016; 23:656-664. [PMID: 27718033 DOI: 10.1245/s10434-016-5602-8] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2016] [Indexed: 11/18/2022]
Abstract
BACKGROUND Breast-conserving surgery (BCS) is the preferred surgical approach for the majority of patients with early-stage breast cancer. There are frequent issues regarding pathologic margin status, requiring margin re-excision, and, in the literature, there is significant variability in re-excision rates, suggesting this is a potential quality-of-care issue. Understanding the patient-, disease-, and physician-related factors influencing reoperation rates is of importance in an effort to minimize this occurrence. METHODS A retrospective analysis of all patients referred to our cancer center over a 3-year period (1 January 2011-31 December 2013) was performed. Surgeon volume, and patient- and tumor-related factors were assessed for their impact on re-excision rates. Multivariate logistic regression analysis was performed to identify variables of significance influencing reoperation rates after attempted BCS. RESULTS Overall, 594 patients underwent initial BCS, with 159 (26.8%) patients requiring at least one re-excision to ensure negative pathologic margins. On multivariate analysis, low surgeon case volume, patient age (under 46 years of age), tumor size (>2 cm), and lobular carcinoma were associated with an increased re-excision rate. CONCLUSION Re-excisions are frequent after BCS and are influenced by surgeon volume, patient age, and tumor-related factors. These factors should be considered when counseling patients considering BCS, and also for quality assurance.
Collapse
Affiliation(s)
- L Hughes
- Department of Surgical Oncology, Sindi Ahluwalia Hawkins Centre for the Southern Interior, BC Cancer Agency, Kelowna, BC, Canada.,University of British Columbia Okanagan, Kelowna, BC, Canada
| | - J Hamm
- Cancer Surveillance and Outcomes, BC Cancer Agency, Vancouver, BC, Canada
| | - C McGahan
- Cancer Surveillance and Outcomes, BC Cancer Agency, Vancouver, BC, Canada
| | - C Baliski
- Department of Surgical Oncology, Sindi Ahluwalia Hawkins Centre for the Southern Interior, BC Cancer Agency, Kelowna, BC, Canada. .,Department of Surgery, University of British Columbia, Vancouver, BC, Canada.
| |
Collapse
|
19
|
Yeung R, Rackley T, Webber B, Hamm J, Lee R, Camborde M, Pearson M, Duzenli C, Loewen S, Liu M, Ma R, Schellenberg D. Stereotactic Body Radiation Therapy for Unresectable Hepatocellular Carcinoma: An Analysis Based on Tumor Size. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.979] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
20
|
Yeung R, Hamm J, Liu M, Schellenberg D. Population-Based Analysis of Stereotactic Body Radiation Therapy for Oligometastatic Lymph Node Disease. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Abstract
Objective: To assess whether patients from non-white ethnic groups wait longer than white patients for elective in-patient admissions at St Mary's Hospital in London. Methods: Patients who came off the waiting list for an elective inpatient admission between 1 April 2000 and 31 March 2001 were selected. A multivariable log linear model was developed to assess geometric mean waiting times for Black, Asian, Other and Missing ethnic groups compared to the White group, adjusted for age, sex, urgency and distance. Results: Caution is needed in interpreting results, as a large number of patients had no usable ethnic code. There was no strong evidence that waiting times for ethnic groups were systematically different than for the White group. However, there was some evidence that white patients waited longer for a coronary arteriography than patients in other ethnic groups. This was partially explained by age, sex, clinical urgency and residential distance from St Mary's. Conclusions: The large proportion of patients with no usable ethnic code, lack of robust methods for case-mix adjustment and multiple ethnic categories makes analysis methodologically difficult. Regular and informative analysis of ethnic coded data is a necessary step in improving the accuracy and completeness of coding.
Collapse
Affiliation(s)
- O W C Morgan
- Public Health Intelligence and Evaluation Unit, Kensington & Chelsea and Westminster Health Authority.
| | | |
Collapse
|
22
|
Rodda S, Duncan G, Hamm J, Morris W. Quality of Life Outcomes: ASCENDE-RT a Multicenter Randomized Trial of Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.012] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
23
|
Rodda S, Tyldesley S, Keyes M, McKenzie M, Pai H, Duncan G, Hamm J, Morris W. Low-Dose-Rate Prostate Brachytherapy Is Superior to Dose-Escalated EBRT for Unfavorable Risk Prostate Cancer: The Results of the ASCENDE-RT Randomized Control Trial. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1038] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
24
|
Patel S, Mehren MV, Reed D, Agulnik M, Kaiser P, Charlson J, Kraft A, Hamm J, Karnad A, Ryan C, Rushing D, Meyer C, Khokhar N, McCarthy S, Park Y, Knoblauch R, Parekh T, Maki R, Demetri G. 3403 Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31878-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
25
|
Salters KA, Cescon A, Zhang W, Ogilvie G, Murray MCM, Coldman A, Hamm J, Chiu CG, Montaner JSG, Wiseman SM, Money D, Pick N, Hogg RS. Cancer incidence among HIV-positive women in British Columbia, Canada: Heightened risk of virus-related malignancies. HIV Med 2015; 17:188-95. [PMID: 26268461 DOI: 10.1111/hiv.12290] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/21/2015] [Indexed: 12/19/2022]
Abstract
OBJECTIVES We used population-based data to identify incident cancer cases and correlates of cancer among women living with HIV/AIDS in British Columbia (BC), Canada between 1994 and 2008. METHODS Data were obtained from a retrospective population-based cohort created from linkage of two province-wide databases: (1) the database of the BC Cancer Agency, a province-wide population-based cancer registry, and (2) a database managed by the BC Centre for Excellence in HIV/AIDS, which contains data on all persons treated with antiretroviral therapy in BC. This analysis included women (≥ 19 years old) living with HIV in BC, Canada. Incident cancer diagnoses that occurred after highly active antiretroviral therapy (HAART) initiation were included. We obtained a general population comparison of cancer incidence among women from the BC Cancer Agency. Bivariate analysis (Pearson χ(2) , Fisher's exact or Wilcoxon rank-sum test) compared women with and without incident cancer across relevant clinical and sociodemographic variables. Standardized incidence ratios (SIRs) were calculated for selected cancers compared with the general population sample. RESULTS We identified 2211 women with 12 529 person-years (PY) of follow-up who were at risk of developing cancer after HAART initiation. A total of 77 incident cancers (615/100 000 PY) were identified between 1994 and 2008. HIV-positive women with cancer, in comparison to the general population sample, were more likely to be diagnosed with invasive cervical cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma and Kaposi's sarcoma and less likely to be diagnosed with cancers of the digestive system. CONCLUSIONS This study observed elevated rates of cancer among HIV-positive women compared to a general population sample. HIV-positive women may have an increased risk for cancers of viral-related pathogenesis.
Collapse
Affiliation(s)
- K A Salters
- BC Centre for Excellence in HIV/AIDS, Vancouver, Canada.,Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
| | - A Cescon
- BC Centre for Excellence in HIV/AIDS, Vancouver, Canada.,Northern Ontario School of Medicine, Sudbury, Canada
| | - W Zhang
- BC Centre for Excellence in HIV/AIDS, Vancouver, Canada
| | - G Ogilvie
- Faculty of Medicine, University of British Columbia, Vancouver, Canada.,BC Centre for Disease Control, Vancouver, Canada
| | - M C M Murray
- Faculty of Medicine, University of British Columbia, Vancouver, Canada.,BC Women's Hospital and Health Centre, Vancouver, Canada.,Women's Health Research Institute, Vancouver, Canada
| | | | - J Hamm
- BC Cancer Agency, Vancouver, Canada
| | - C G Chiu
- Department of Surgery, St Paul's Hospital & University of British Columbia, Vancouver, Canada
| | - J S G Montaner
- BC Centre for Excellence in HIV/AIDS, Vancouver, Canada.,Faculty of Medicine, University of British Columbia, Vancouver, Canada
| | - S M Wiseman
- Department of Surgery, St Paul's Hospital & University of British Columbia, Vancouver, Canada
| | - D Money
- Faculty of Medicine, University of British Columbia, Vancouver, Canada.,BC Women's Hospital and Health Centre, Vancouver, Canada.,Women's Health Research Institute, Vancouver, Canada
| | - N Pick
- Faculty of Medicine, University of British Columbia, Vancouver, Canada.,BC Women's Hospital and Health Centre, Vancouver, Canada.,Women's Health Research Institute, Vancouver, Canada
| | - R S Hogg
- BC Centre for Excellence in HIV/AIDS, Vancouver, Canada.,Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
| |
Collapse
|
26
|
Morris W, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, Hamm J. OC-0485: LDR brachytherapy is superior to 78 Gy of EBRT for unfavourable risk prostate cancer: the results of a randomized trial. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40481-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Hamilton S, Tyldesley S, Hamm J, Keyes M, Pickles T, Lapointe V, Kahnamelli A, McKenzie M, Miller S, Morris W. The Incidence of Second Malignancies Following Low-Dose-Rate Brachytherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
28
|
Samuels BL, Chawla S, Patel S, von Mehren M, Hamm J, Kaiser PE, Schuetze S, Li J, Aymes A, Demetri GD. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol 2013; 24:1703-9. [PMID: 23385197 DOI: 10.1093/annonc/mds659] [Citation(s) in RCA: 105] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND This expanded access program (EAP) was designed to provide trabectedin access for patients with incurable soft tissue sarcoma (STS) following progression of disease with standard therapy. The outcomes of trial participants accrued over approximately 5 years are reported. PATIENTS AND METHODS Adult patients with advanced STS of multiple histologies, including leiomyosarcoma and liposarcoma (L-sarcomas), following relapse or disease progression following standard-of-care chemotherapy, were enrolled. Trabectedin treatment cycles (1.5 mg/m(2), intravenously over 24 h) were repeated q21 days. Objective response, overall survival (OS), and safety were evaluated. RESULTS Of 1895 patients enrolled, 807 (43%) had evaluable objective response data, with stable disease reported in 343 (43%) as best response. L-sarcoma patients exhibited longer, OS compared with other histologies [16.2 months (95% confidence interval (CI) 14.1-19.5) versus 8.4 months (95% CI 7.1-10.7)], and a slightly higher objective response rate [6.9% (95% CI 4.8-9.6) versus 4.0% (95% CI 2.1-6.8)]. The median treatment duration was 70 days representing a median of three treatment cycles; 30% of patients received ≥ 6 cycles. Safety and tolerability in this EAP were consistent with prior clinical trial data. CONCLUSION Results of this EAP are consistent with previous reports of trabectedin, demonstrating disease control despite a low incidence of objective responses in advanced STS patients after failure of standard chemotherapy. CLINICALTRIALS.GOV: NCT00210665.
Collapse
Affiliation(s)
- B L Samuels
- Department of Medical Oncology, Kootenai Cancer Center, Post Falls, ID 83854, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Fayez R, AlMuntashery A, Bodie G, Almamar A, Gill R, Raîche I, Mueller C, AlMuntashery A, Fayez R, AlMuntashery A, Moustarah F, Khokhotva M, Anvari M, Kwong J, Elkassem S, Bonrath E, Zevin B, Sockalingam S, Smith C, Smith C, Whitlock K, Gill R, Suri M, Palter V, Wakeam E, Khan R, Martelli V, Malik A, Young P, Daigle C, McCreery G, Seth R, Paskar D, Sudarshan M, Richardson D, Haggar F, Davis V, Rivard J, Agzarian J, Racz J, Winocour J, Zilbert N, Decker C, Neumann K, Gosney J, Wissanji H, Chadi S, Alhabboubi M, Partridge E, Alhabboubi M, Olszewski M, Chan R, Nadler A, Hameed U, Brotherhood H, Menezes A, MacDonald B, Rakovich G, Hilsden R, Merani S, Davis P, Davis P, Cools-Lartigue J, Ojah J, Julien F, Carter D, Pitt D, Banks B, Rudovics A, Ravichandran P, Anantha R, Aad I, Kholdebarin R, Aird L, Wong S, Payne J, Hallet J, Farries L, Raiche I, Botkin C, Morency D, Berger-Richardson D, Isa A, Dupuis I, Schweigert M, Koubi S, Ernjakovic M, Grant K, Cools-Lartigue J, Carrott P, Stafford T, Malthaner R, Sudarshan M, Hanna W, Lee L, Markar S, Razzak R, Bharadwaj S, Ashrafi A, Ouellette D, Fergusson D, Forster A, Boushey R, Porter G, Johnson P, Gomes T, Chan B, Auer R, Moloo H, Mamdani M, Markar S, Al-Omran M, Al-Obaid O, Boushey R, Lim DR, Min BS, Baik SH, Gordon P, Kim NK, Lo A, Pinsk I, Bottoni D, Brown C, Raval M, Cheng H, Wong C, Johnston N, Farrokhyar F, Stephen W, Kelly S, Lindsay L, Forbes S, Knickle C, Bouchard A, Parry N, Leslie K, Ott M, Coughlin S, Gazala S, Gazala S, Donahoe L, Walker K, Li C, Alnasser S, Schweigert M, Schweigert M, Zhuruk A, Hanouf A, Vanounou T, Karanicolas P, Aubin JM, Yeung J, Dumitra S, Simoneau E, Vanounou T, Howe B, Hawel J, Jang JH, Bertens K, Rekman J, Wei A, Dumitra S, Koubi S, Ouellet JF, Wei A, Covelli A, Maniar R, Sun S, Davis V, Brackstone M, Boissonneault R, Kim S, Baliski C, Gazala S, Hameed U, Sudarshan M, Arnaout A, Wedman D, Nostedt M, Hebbard P, Shetty S, Dixon M, Wei A, Dixon M, Kazazian K, Lemke M, Wells B, Musselman R, Zih FSW, Menezes A, Nassif M, Leon-Carlyle M, Wei A, Krotneva S, Bradley N, Trabulsi N, Trabulsi N, Chin-Lenn L, Cheng H, Petrucci A, Sandhu L, Neville A, Lee L, Li C, Yang I, Prabhu KL, Melich G, Knowles S, Richardson D, Borowiec A, Hallet J, Boissonneault R, Kolozsvari N, Hallet J, Tuttle P, VanHouwelingen L, Haggar F, Boulanger-Gobeil C, Chan B, Chan B, Richardson D, Musselman R, Melich G, Phang P, Goldstein L, Wen C, Lebrun A, Chadi S, Roy M, Villeneuve S, AlMuntashery A, Demyttenaere S, Christou N, Court O, Fayez R, Demyttenaere S, Christou N, Court O, Bonrath E, Hagen J, Okrainec A, Sullivan P, Grantcharov T, Sharma A, Karmali S, Birch D, Majumdar S, Wang X, Tuepah R, Klarenbach S, Birch D, Karmali S, Sharma A, Padwal R, Smith C, Haggar F, Moloo H, Poulin E, Martel G, Yelle JD, Mamazza J, Jackson T, Penner T, Pitzul K, Urbach D, Okrainec A, Villeneuve S, Roy M, Fayez R, Demyttenaere S, Christou N, Court O, Roy M, Villeneuve S, AlMuntashery A, Demyttenaere S, Christou N, Court O, Fayez R, Demyttenaere S, Court O, Christou N, Biertho L, Hould FS, Lebel S, Lescelleur O, Marceau S, Marceau P, Biron S, Grantcharov T, Sharma A, Yusuf S, Okrainec A, Pitzul K, Urbach D, Jackson T, Lindsay D, Sullivan P, Smith L, Zevin B, Dedy N, Grantcharov T, Bonrath E, Aggarwal R, Grantcharov T, Cassin S, Crawford S, Pitzul K, Khan A, Hawa R, Jackson T, Okrainec A, Brar B, Mamazza J, Raîche I, Yelle JD, Haggar F, Moloo H, Brar B, Haggar F, Dent R, Mamazza J, Raîche I, Moloo H, Gill R, Ali T, Shi X, Birch D, Karmali S, Whitlock K, Shi X, Sarkhosh K, Birch D, Karmali S, Turner J, Nation P, Wizzard P, Brubaker P, Gisalet D, Wales P, Grantcharov T, Tien H, Spencer F, Brenneman F, Kowal J, Wiseman S, Fraser S, Vedel I, Deban M, Holcroft C, Monette M, Monette J, Bergman S, Bell C, Stukel T, Urbach D, Mueller T, Lucykx V, Lukowski C, Compston C, Churchill T, Khadaroo R, Grantcharov T, Vogt K, Dubois L, Gray D, Ananth A, Tai LH, Lam T, Falls T, Souza C, Bell J, Auer R, Crawford S, Parry N, Leslie K, Alhabboubi M, St-Louis E, Deckelbaum D, Razek T, Feldman L, Khwaja K, Porter G, Johnson P, Boushey R, Moloo H, Raiche I, Mamazza J, Schiller D, Eurich D, Sawyer M, Vergis A, Unger B, Hardy K, Andrew C, Gillman L, Park J, Prodger J, Kelly W, Kelly S, Prodger D, Ewara E, Martin J, Sarma S, Chu M, Schlachta C, Zaric G, Al-Ali K, Briggs K, George R, Murnaghan M, Leung A, Regehr G, Moulton CA, Mahmud S, Metcalfe J, McKay A, Park J, Hochman D, Burkle F, Redmond A, McQueen K, Desrosiers E, Gilbert A, Leslie K, Ott M, Sudarshan M, Jessula S, Alburakan A, Deckelbaum D, Razek T, Iqbal S, Khwaja K, Aikins C, Sudarshan M, Deckelbaum D, Iqbal S, Khwaja K, Razek T, Roberts N, Moulton CA, Murnaghan M, Cil T, Marshall J, Pederson K, Erichsen S, White J, Aarts MA, Okrainec A, Victor J, Pearsall E, McLeod R, Jackson T, Okrainec A, Penner T, Urbach D, Karimuddin A, Hall C, Bawan S, Malik S, Hayashi A, Gill R, McAlister C, Zhang N, DesRosiers E, Mills A, Crozier M, Lee L, Maxwell J, Partridge E, Chad S, Steigerwald S, Mapiour D, Roberts D, MacPherson C, Donahoe L, Mercer D, Hopman W, Latulippe JF, Knowles S, Moffat B, Parry N, Leslie K, Switzer N, Khadaroo R, Tul Y, Widder S, Molinari M, Levy A, Johnson P, Bailey J, Molinari M, Hayden J, Johnson P, Benlolo S, Marcus V, Ferri L, Finley R, Anderson D, Gagné JP, Chan S, Wong S, Li J, Michael A, Choi D, Liu E, Hoogenes J, Dath D, Aubin JM, Mew D, McConnell Y, Classen D, Kanthan S, Croome K, Kovacs M, Lazo-Langner A, Hernandez-Alejandro R, Vogt K, Crawford S, Parry N, Leslie K, Khoshgoo N, Iwasiow B, Keijzer R, Brown C, Isa D, Pace D, Widder S, Tul Y, Primrose M, Hudson D, Khadaroo R, Lauzier F, Mailloux O, Trottier V, ARchambault P, Zarychanski R, Turgeon A, Mailloux O, Hardy P, Muirhead R, Masters J, Haggar F, Poulin HME, Martel G, Mamazza J, Milbrandt C, Keijzer R, Sideris L, Grenier-Vallée P, Latulippe JF, Dubé P, Kurashima Y, Kaneva P, Feldman L, Fried G, Vassiliou M, Kwan AL, Fraser S, Solymosi N, Rauh N, Dubecz A, Renz M, Ofner D, Stein H, Borgaonkar M, Crystal P, Easson A, Escallon J, Reedijk M, Cil T, Leong W, McCready D, Clifton J, Mayo J, Finley R, Noreau-Nguyen M, Mulder D, Ferri L, Markar S, Hong J, Low D, Maslow A, Davignon K, Ng T, Tan L, Aruranian J, Kosa S, Ferri L, Murphy G, Allison F, Moshonov H, Darling G, Waddell T, De Perrot M, Cypel M, Yasufuku K, Keshavjee S, Paul N, Pierre A, Darling G, Pedneault C, Marcus V, Mulder D, Ferri L, Low D, Roa W, Löbenberg R, McEwan S, Bédard E, Louie B, Farivar A, McHugh S, Aye R, Tan-Tam C, De Vera M, Bond R, Ong S, Johal B, Schellenberg D, Po M, Nissar S, Lund C, Ahmadi S, Wakil N, Rakovich G, Beauchamps G, Preston S, Baker C, Low D, Campbell G, Malthaner R, Bethune D, Henteleff H, Johnston M, Buduhan G, Coughlin HE, Roth L, Bhandari M, Malthaner R, Johnson J, Kutsogiannis J, Bédard E, Rammohan K, Stewart K, Bédard E, Buduhan G, Gruchy J, Xu Z, Buduhan G, Ferri L, Mulder D, Ncuti A, Neville A, Kaneva P, Watson D, Vassiliou M, Carli F, Feldman L, Av R, Mayrand S, Franco E, Ferri L, Dubecz A, Renz M, Stadlhuber R, Ofner D, Stein H, Renz M, Dubecz A, Solymosi N, Thumfart L, Ofner D, Stein H, Croome K, Leeper R, Hernandez R, Livingstone S, Sapp J, Woodhall D, Alwayn I, Bergman S, Lam-McCulloch J, Balaa F, Jayaraman S, Quan D, Wei A, Guyatt G, Rekman J, Fairfull-Smith R, Mimeault R, Balaa F, Martel G, Boehnert M, Bazerbachi F, Knaak J, Selzner N, McGilvray I, Rotstein O, Adeyi O, Levy G, Keshavjee S, Grant D, Selzner M, Khalil JA, Jamal M, Chaudhury P, Zogopoulos G, Petrakos P, Tchervenkov J, Barkun J, Jamal M, Hassanain M, Chaudhury P, Wong S, Salman A, Tran T, Metrakos P, Groeschl R, Geller D, Marsh J, Gamblin T, Croome K, Croome K, Quan D, Hernandez R, Kim P, Greig PD, Gallinger S, Moulton CA, Wei A, Fischer S, Cleary S, Vogt K, Hernandez-Alejandro R, Gray D, Aubin J, Fairfull-Smith J, Mimeault R, Balaa F, Martel G, Devitt K, Ramjaun A, Gallingher S, Alabbad S, Constantinos D, Hassanein M, Barkun J, Metrakos P, Paraskevas S, Chaudhury P, Tchervenkov J, Borgaonkar M, Tanyingoh D, Dixon E, Kaplan G, Myers R, Howard T, Sutherland F, Zyromski N, Ball C, Coburn N, Moulton CA, Cleary S, Law C, Greig P, Steven G, Baxter N, Fitch M, Wright F, Hochman D, Wirtzfeld D, McKay A, Yaffe C, Yip B, Silverman R, Park J, McConnell Y, Temple W, Mack L, Schiller D, Bathe O, Sawyer M, Scott L, Vandenberg T, Perera F, Potvin K, Chambers A, Loungnarath R, DeBroux É, Lavertu S, Donath D, Ayoub JP, Tehfé M, Richard C, Cornacchi S, Heller B, Farrokhyar F, Babra M, Lovrics P, Liberto C, Ghosh S, McLean R, Schiller D, Jackson T, Okrainec A, Penner T, Urbach D, Dumitra S, Duplisea J, Wexler S, Seely J, Smylie J, Knight K, Robertson S, Watters J, Zhang T, Arneout A, Hochman D, Wirtzfeld D, McKay A, Yip B, Yaffe C, Silverman R, Park J, Baxter N, Yun L, Rakovitch E, Wright F, Warner E, McCready D, Hodgson N, Quan M, Natarajan B, Govindarajan V, Thomas P, Loggie B, Brar S, Mahar A, Law C, Coburn N, Devitt K, Wiebe M, Bathe O, McLeod R, Baxter N, Gagliardi A, Kennedy E, Urbach D, Brar S, Mahar A, Law C, Coburn N, Zih F, Rosario C, Dennis J, Gingras AC, Swallow C, Ko YJ, Rowsell C, Law C, Saskin R, Quan ML, Xie M, McLaughlin K, Marginean C, Moyana T, Moloo H, Boushey R, Auer R, Razik R, Haase E, Mathieson A, Smith A, Swallow C, Barnes A, Scheer A, Moloo H, Boushey R, Sabri E, Auer R, Reidel K, Trabulsi N, Meterissian S, Tamblyn R, Mayo N, Meguerditchian A, Brown J, Hamm J, Phang P, Raval M, Brown C, Devitt K, Wiebe M, Bathe O, McLeod R, Taylor B, Urbach D, Reidel K, Mayo N, Tamblyn R, Meguerditchian A, Hamm J, Wiseman S, Patakfalvi L, Nassif M, Turcotte R, Nichols A, Meguerditchian A, Riedel K, Winslade N, Grégoire JP, Meterissian S, Abrahamovicz M, Megueerditchian A, Pasieka J, McMillan C, Lipa J, Snell L, Sudarshan M, Dumitra S, Duplisea J, Wexler S, Meterissian S, Tomlinson G, Kennedy E, Wei A, Baxter N, Urbach D, Liberman A, Charlebois P, Stein B, Ncuti A, Vassiliou M, Fried G, Feldman L, Capretti G, Power A, Liberman A, Charlebois P, Stein B, Kaneva P, Carli F, Fried G, Feldman L, Carli F, Charlebois P, Stein B, Liberman A, Kaneva P, Augustin B, Gamsa A, Kim DJ, Vassiliou M, Feldman L, Boushey R, Moloo H, Vu L, Chan S, Phang P, Gown A, Jones S, Wiseman S, Jeong DH, Hur H, Baik SH, Kim NK, Faria J, Min BS, Lumb K, Colquhoun P, Porter G, Johnson P, Baxter N, Schmocker S, Huang H, Victor J, Krzyzanowska MK, Brierley J, McLeod R, Kennedy E, Milot H, Desrosiers E, Lebrun A, Drolet S, Bouchard A, Grégoire R, Vuong T, Loungnarath R, DeBroux E, Liberman A, Charlebois P, Stein B, Richard C, Capretti G, Kaneva P, Neville A, Carli F, Liberman S, Charlebois P, Stein B, Vassiliou M, Fried G, Feldman L, Milot H, Drolet S, Bouchard A, Grégoire R, Powell R, Fowler A, Mathieson A, Martin K, Vogt K, Ott M, Pereira G, Einarsdottir K, Moloo H, Boushey R, Mamazza J, Bouchard A, Gagné J, Grégoire R, Thibault C, Bouchard P, Gomes T, Musselman R, Auer R, Moloo H, Mamdani M, Al-Omran M, Boushey R, AlObeed O, Armstrong J. Canadian Surgery Forum1 Is laparoscopic sleeve gastrectomy a reasonable stand-alone procedure for super morbidly obese patients?2 Postoperative monitoring requirements of patients with obstructive sleep apnea undergoing bariatric surgery3 Role of relaparoscopy in the diagnosis and treatment of bariatric complications in the early postoperative period4 Changes of active and total ghrelin, GLP-1 and PYY following restrictive bariatric surgery and their impact on satiety: comparison of sleeve gastrectomy and adjustable gastric banding5 Prioritization and willingness to pay for bariatric surgery: the patient perspective6 Ventral hernia at the time of laparoscopic gastric bypass surgery: Should it be repaired?7 Linear stapled gastrojejunostomy with transverse handsewn enterotomy closure significantly reduces strictures for laparoscopic Roux-en-Y bypass8 Laparoscopic biliopancreatic diversion with duodenal switch as second stage for super super morbidly obese patients. Do all patients benefit?9 Sleeve gastrectomy in the super super morbidly obese (BMI > 60 kg/m2): a Canadian experience10 Laparoscopic gastric bypass for the treatment of refractory idiopathic gastroparesis: a report of 2 cases11 Duodeno-ileal switch as a primary bariatric and metabolic surgical option for the severely obese patient with comorbidities: review of a single-institution case series of duodeno-ileal intestinal bypass12 Management of large paraesophageal hernias in morbidly obese patients with laparoscopic sleeve gastrectomy: a case series13 Early results of the Ontario bariatric surgical program: using the bariatric registry14 Improving access to bariatric surgical care: Is universal health care the answer?15 Early and liberal postoperative exploration can reduce morbidity and mortality in patients undergoing bariatric surgery16 Withdrawn17 Identification and assessment of technical errors in laparoscopic Roux-en-Y gastric bypass18 A valid and reliable tool for assessment of surgical skill in laparoscopic Roux-en-Y gastric bypass19 Psychiatric predictors of presurgery drop-out following suitability assessment for bariatric surgery20 Predictors of outcomes following Roux-en-Y gastric bypass surgery at The Ottawa Hospital21 Prophylactic management of cholelithiasis in bariatric patients: Is routine cholecystectomy warranted?22 Early outcomes of Roux-en-Y gastric bypass in a publicly funded obesity program23 Similar incidence of gastrojejunal anastomotic stricture formation with hand-sewn and 21 mm circular stapler techniques during Roux-en-Y gastric bypass24 (CAGS Basic Science Award) Exogenous glucagon-like peptide-1 improves clinical, morphological and histological outcomes of intestinal adaptation in a distal-intestinal resection piglet model of short bowel syndrome25 (CAGS Clinical Research Award) Development and validation of a comprehensive curriculum to teach an advanced minimally invasive procedure: a randomized controlled trial26 Negative-pressure wound therapy (iVAC) on closed, high-risk incisions following abdominal wall reconstruction27 The impact of seed granting on research in the University of British Columbia Department of Surgery28 Quality of surgical care is inadequate for elderly patients29 Recurrence of inguinal hernia in general and hernia specialty hospitals in Ontario, Canada30 Oncostatin M receptor deficiency results in increased mortality in an intestinal ischemia reperfusion model in mice31 Laparoscopic repair of large paraesophageal hernias with anterior gastropexy: a multicentre trial32 Response to preoperative medical therapy predicts success of laparoscopic splenectomy for immune thrombocytopenic purpura33 Perioperative sepsis, but not hemorrhagic shock, promotes the development of cancer metastases in a murine model34 Measuring the impact of implementing an acute care surgery service on the management of acute biliary disease35 Patient flow and efficiency in an acute care surgery service36 The relationship between treatment factors and postoperative complications after radical surgery for rectal cancer37 Risk of ventral hernia after laparoscopic colon surgery38 Urinary metabolomics as a tool for early detection of Barrett’s and esophageal cancer39 Construct validity of individual and summary performance metrics associated with a computer-based laparo-scopic simulator40 Impact of a city-wide health system reorganization on emergency department visits in hospitals in surrounding communities41 Transcatheter aortic valve implantation for the nonoperative management of aortic stenosis: a cost-effectiveness analysis42 Breast cancer: racial differences in age of onset. A potential confounder in Canadian screening recommendations43 Risk taking in surgery: in and out of the comfort zone44 A tumour board in the office: Track those cancer patients!45 Increased patient BMI is not associated with advanced colon cancer stage or grade on presentation: a retrospective chart review46 Consensus statements regarding the multidisciplinary care of limb amputation patients in disasters or humanitarian emergencies. Report of the 2011 Humanitarian Action Summit Surgical Working Group on amputations following disasters or conflict47 Learning the CanMEDS role of professional: a pilot project of supervised discussion groups addressing the hidden curriculum48 Assessing the changing scope of training in Canadian general surgery programs: expected versus actual experience49 Predicting need for surgical management for massive gastrointestinal hemorrhage50 International health care experience: using CanMEDS to evaluate learning outcomes following a surgical mission in Mampong, Ghana51 The open abdomen: risk factors for mortality and rates of closure52 How surgeons think: an exploration of mental practice in surgical preparation53 The surgery wiki: a novel method for delivery of under-graduate surgical education54 Understanding surgical residents’ postoperative practices before implementing an enhanced recovery after surgery (ERAS) guideline at the University of Toronto55 From laparoscopic transabdominal to posterior retroperitoneal adrenalectomy: a paradigm shift in operative approach56 A retrospective audit of outcomes in patients over the age of 80 undergoing acute care abdominal surgery57 Canadian general surgery residents’ perspectives on work-hour regulations58 Timing of surgical intervention and its outcomes in acute appendicitis59 Preparing surgical trainees to deal with adverse events. An outline of learning issues60 Acute care surgical service: surgeon agreement at the time of handover61 Predicting discharge of elderly patients to prehospitalization residence following emergency general surgery62 Morbidity and mortality after emergency abdominal surgery in octo- and nonagenarians63 The impact of acute abdominal illness and urgent admission to hospital on the living situation of elderly patients64 A comparison of laparoscopic versus open subtotal gastrectomy for antral gastric adenocarcinoma: a North American perspective65 Minimally invasive excision of ectopic mediastinal parathyroid adenomas66 Perioperative outcomes of laparoscopic hernia repair in a tertiary care centre: a single institution’s experience67 Evaluation of a student-run, practical and didactic curriculum for preclerkship medical students68 Joseph Lister: Father of Modern Surgery69 Comparisons of melanoma sentinel lymph node biopsy prediction nomograms in a cohort of Canadian patients70 Local experience with myocutaneous flaps after extensive pelvic surgery71 The treatment of noncirrhotic splanchnic vein thrombosis: Is anticoagulation enough?72 Implementation of an acute care surgery service does not affect wait-times for elective cancer surgeries: an institutional experience73 Use of human collagen mesh for closure of a large abdominal wall defect, after colon cancer surgery, a case report74 The role of miR-200b in pulmonary hypoplasia associated with congenital diaphragmatic hernia75 Systematic review and meta-analysis of electrocautery versus scalpel for incising epidermis and dermis76 Accuracy of sentinel lymph node biopsy for early breast cancer in the community setting in St. John’s, New-foundland: results of a retrospective review77 Acute surgical outcomes in the 80 plus population78 The liberal use of platelets transfusions in the acute phase of trauma resuscitation: a systematic review79 Implementation of an acute care surgical on call program in a Canadian community hospital80 Short-term outcomes following paraesophageal hernia repair in the elderly patient81 First experience with single incision surgery: feasibility in the pediatric population and cost evaluation82 The impact of the establishment of an acute care surgery unit on the outcomes of appendectomies and cholecystectomies83 Description and preliminary evaluation of a low-cost simulator for training and evaluation of flexible endoscopic skills84 Tumour lysis syndrome in metastatic colon cancer: a case report85 Acute care surgery service model implementation study at a single institution86 Colonic disasters approached by emergent subtotal and total colectomy: lessons learned from 120 consecutive cases87 Acellular collagen matrix stent to protect bowel anastomoses88 Lessons we learned from preoperative MRI-guided wire localization of breast lesions: the University Health Network (UHN) experience89 Interim cost comparison for the use of platinum micro-coils in the operative localization of small peripheral lung nodules90 Routine barium esophagram has minimal impact on the postoperative management of patients undergoing esophagectomy for esophageal cancer91 Iron deficiency anemia is a common presenting issue with giant paraesophageal hernia and resolves following repair92 A randomized comparison of different ventilation strategies during thoracotomy and lung resection93 The Canadian Lung Volume Reduction Surgery study: an 8-year follow-up94 A comparison of minimally invasive versus open Ivor-Lewis esophagectomy95 A new paradigm in the follow-up after curative resection for lung cancer: minimal-dose CT scan allows for early detection of asymptomatic cancer activity96 Predictors of lymph node metastasis in early esophageal adenocarcinoma: Is endoscopic resection worth the risk?97 How well can thoracic surgery residents operate? Comparing resident and program director opinions98 The impact of extremes of age on short- and long-term outcomes following surgical resection of esophageal malignancy99 Epidermal growth factor receptor targeted gold nanoparticles for the enhanced radiation treatment of non–small cell lung cancer100 Laparoscopic Heller myotomy results in excellent outcomes in all subtypes of achalasia as defined by the Chicago classification101 Neoadjuvant chemoradiation versus surgery in managing esophageal cancer102 Quality of life postesophagectomy for cancer!103 The implementation, evolution and translocation of standardized clinical pathways can improve perioperative outcomes following surgical treatment of esophageal cancer104 A tissue-mimicking phantom for applications in thoracic surgical simulation105 Sublobar resection compared with lobectomy for early stage non–small cell lung cancer: a single institution study106 Not all reviews are equal: the quality of systematic reviews and meta-analyses in thoracic surgery107 Do postoperative complications affect health-related quality of life after video-assisted thoracoscopic lobectomy for patients with lung cancer? A cohort study108 Thoracoscopic plication for palliation of dyspnea secondary to unilateral diaphragmatic paralysis: A worthwhile venture?109 Thoracic surgery experience in Canadian general surgery residency programs110 Perioperative morbidity and pathologic response rates following neoadjuvant chemotherapy and chemoradiation for locally advanced esophageal carcinoma111 An enhanced recovery pathway reduces length of stay after esophagectomy112 Predictors of dysplastic and neoplastic progression of Barrett’s esophagus113 Recurrent esophageal cancer complicated by tracheoesophageal fistula: management by means of palliative airway stenting114 Pancreaticopleural fistula-induced empyema thoracis: principles and results of surgical management115 Prognostic factors of early postoperative mortality following right extended hepatectomy116 Optimizing steatotic livers for transplantation using a cell-penetrating peptide CPP-fused heme oxygenase117 Video outlining the technical steps for a robot-assisted laparoscopic pancreaticoduodenectomy118 Establishment of a collaborative group to conduct innovative clinical trials in Canada119 Hepatic resection for metastatic malignant melanoma: a systematic review and meta-analysis120 Acellular normothermic ex vivo liver perfusion for donor liver preservation121 Pancreatic cancer and predictors of survival: comparing the CA 19–9/bilirubin ratio with the McGill Brisbane Scoring System122 Staged liver resections for bilobar hepatic colorectal metastases: a single centre experience123 Economic model of observation versus immediate resection of hepatic adenomas124 Resection of colorectal liver metastasis in the elderly125 Acceptable long-term survival in patients undergoing liver resection for metastases from noncolorectal, non-neuroendocrine, nonsarcoma malignancies126 Patient and clinicopathological features and prognosis of CK19+ hepatocellular carcinomas: a case–control study127 The management of blunt hepatic trauma in the age of angioembolization: a single centre experience128 Liver resections for noncolorectal and non-neuroendocrine metastases: an evaluation of oncologic outcomes129 Developing an evidence-based clinical pathway for patients undergoing pancreaticoduodenectomy130 Hepatitis C infection and hepatocellular carcinoma in liver transplant: a 20 year experience131 The effect of medication on the risk of post-ERCP pancreatitis132 Temporal trends in the use of diagnostic imaging for patients with hepato-pancreato-biliary (HPB) conditions: How much ionizing radiation are we really using?196 A phase II study of aggressive metastasectomy for intra-and extrahepatic metastases from colorectal cancer133 Why do women choose mastectomy for breast cancer treatment? A conceptual framework for understanding surgical decision-making in early-stage breast cancer134 Synoptic operative reporting: documentation of quality of care data for rectal cancer surgery135 Learning curve analysis for cytoreductive surgery: a useful application of the cumulative sum (CUSUM) method136 Pancreatic cancer is strongly associated with a unique urinary metabolomic signature137 Concurrent neoadjuvant chemo/radiation in locally advanced breast cancer138 Impact of positron emission tomography on clinical staging of newly diagnosed rectal cancer: a specialized single centre retrospective study139 An evaluation of intraoperative Faxitron microradiography versus conventional specimen radiography for the excision of nonpalpable breast lesions140 Comparison of breast cancer treatment wait-times in the Southern Interior of British Columbia in 2006 and 2010141 Factors affecting lymph nodes harvest in colorectal carcinoma142 Laparoscopic adrenalectomy for metastases143 You have a message! Social networking as a motivator for fundamentals of laparoscopic surgery (FLS) training144 The evaluation and validation of a rapid diagnostic and support clinic for women assessment for breast cancer145 Oncoplastic breast surgery: oncologic benefits and limitations146 A qualitative study on rectal cancer patients’ preferences for location of surgical care147 The effect of surgery on local recurrence in young women with breast cancer148 Elevated IL-6 and IL-8 levels in tumour microenvironment is not associated with increased serum levels in humans with Pseudomyxoma peritonei and peritoneal mesothelioma149 Conversion from laparoscopic to open approach during gastrectomy: a population-based analysis150 A scoping review of surgical process improvement tools (SPITs) in cancer surgery151 Splenectomy during gastric cancer surgery: a population-based study152 Defining the polo-like kinase 4 (Plk4) interactome in cancer cell protrusions153 Neoadjuvant imatinib mesylate for locally advanced gastrointestinal stromal tumours154 Implementing results from ACOSOG Z0011: Practice-changing or practice-affirming?155 Should lymph node retrieval be a surgical quality indicator in colon cancer?156 Long-term outcomes following resection of retroperitoneal recurrence of colorectal cancer157 Clinical research in surgical oncology: an analysis of clinicaltrials.gov158 Radiation therapy after breast conserving surgery: When are we missing the mark?159 The accuracy of endorectal ultrasound in staging rectal lesions in patients undergoing transanal endoscopic microsurgery160 Quality improvement in gastrointestinal cancer surgery: expert panel recommendations for priority research areas161 Factors influencing the quality of local management of ductal carcinoma in situ: a cohort study162 Papillary thyroid microcarcinoma: Does size matter?163 Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: systematic review of clinical efficacy and quality assessment of reported trials164 Adherence to antiestrogen therapy in seniors with breast cancer: How well are we doing?165 Parathyroid carcinoma: Challenging the surgical dogma?166 A qualitative assessment of the journey to delayed breast reconstruction195 The role of yoga therapy in breast cancer patients167 Outcomes reported in comparative studies of surgical interventions168 Enhanced recovery pathways decrease length of stay following colorectal surgery, but how quickly do patients actually recover?169 The impact of complications on bed utilization after elective colorectal resection170 Impact of trimodal prehabilitation program on functional recovery after colorectal cancer surgery: a pilot study171 Complex fistula-in-ano: Should the plug be abandoned in favour of the LIFT or BioLIFT?172 Prognostic utility of cyclooxygenase-2 expression by colon and rectal cancer173 Laparoscopic right hemicolectomy with complete mesocolic excision provides acceptable perioperative outcomes but is complex and time-consuming: analysis of learning curves for a novice minimally invasive surgeon174 Intraoperative quality assessment following double stapled circular colorectal anastomosis175 Improving patient outcomes through quality assessment of rectal cancer care176 Are physicians willing to accept a decrease in treatment effectiveness for improved functional outcomes for low rectal cancer?177 Turnbull-Cutait delayed coloanal anastomosis for the treatment of distal rectal cancer: a prospective cohort study178 Preoperative high-dose rate brachytherapy in preparation for sphincter preservation surgery for patients with advanced cancer of the lower rectum179 Impact of an enhanced recovery program on short-term outcomes after scheduled laparoscopic colon resection180 The clinical results of the Turnbull-Cutait delayed coloanal anastomosis: a systematic review181 Is a vertical rectus abdominus flap (VRAM) necessary? An analysis of perineal wound complications182 Fistula plug versus endorectal anal advancement flap for the treatment of high transsphincteric cryptoglandular anal fistulas: a systematic review and meta-analysis183 Maternal and neonatal outcomes following colorectal cancer surgery184 Transanal drainage to treat anastomotic leaks after low anterior resection for rectal cancer: a valuable option185 Trends in colon cancer in Ontario: 2002–2009186 Validation of electronically derived short-term outcomes in colorectal surgery187 A population-based assessment of transanal and endoscopic resection for adenocarcinoma of the rectum188 Laparoscopic colorectal surgery in the emergency setting: trends in the province of Ontario from 2002 to 2009189 Prevention of perineal hernia after laparoscopic and robotic abdominoperineal resection: review with case series of internal hernia through pelvic mesh which was placed in attempt to prevent perineal hernia190 Effect of rectal cancer treatments on quality of life191 The use of antibacterial sutures as an adjunctive preventative strategy for surgical site infection in Canada: an economic analysis192 Impact of socioeconomic status on colorectal cancer screening and stage at presentation: preliminary results of a population-based study from an urban Canadian centre193 Initial perioperative results of the first transanal endoscopic microsurgery (TEM) program in the province of Quebec194 Use of negative pressure wound therapy decreases perineal wound infections following abdominal perineal resection. Can J Surg 2012; 55:S63-S135. [DOI: 10.1503/cjs.016712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
30
|
Tyldesley S, Tran E, Paquette M, Jay J, Liu M, Hamm J, Duncan G, Pickles T. OC-0049 THE IMPACT OF COMORBIDITIES ON THE BENEFITS OF PROLONGED ANDROGEN ABLATION IN PATIENTS WITH T3-4 PROSTATE CANCER. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)70388-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
31
|
Carlson R, Morris W, Moiseenko V, Tyldesley S, Kosztyla R, Hamm J, Hui J, Jackson J, Sahota H, Liu M. The Toxicity of Dose Escalated External Beam Radiation Therapy after Elective Pelvic Nodal Irradiation: Evaluating the Utility of the QUANTEC Rectal Dose Thresholds. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
32
|
Tran E, Tyldesley S, Paquette M, Hamm J, Liu M, Lim J, Keyes M, Kwan W, Pickles T. Population-based Validation of the Bolla Study in T3-4 Prostate Cancer in British Columbia. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
|
34
|
|
35
|
|
36
|
Chiorean E, Dragovich T, Hamm J, Barrios C, Gorini C, Langmuir V, Kroll S, Tidmarsh G, Colowick A, Loehrer P. 3523 POSTER Glufosfamide (GLU) plus gemcitabine (GEM) in pancreatic adenocarcinoma: results of a Phase 2 trial. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71026-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
37
|
Nemunaitis JJ, Clayman G, Hamm J, Bier-Laning C, Minn H, Van Echo D, Yoo G, Menander K, Sobol RE, Goodwin WJ. Tumor response criteria and biomarkers associated with increased survival following adenoviral p53 gene therapy (ADVEXIN) in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.6057] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6057 Background: There is a growing body of data indicating that conventional WHO and RECIST criteria do not optimally identify tumor responses associated with increased survival. Methods: We compared several response criteria to assess the efficacy of intratumoral adenoviral p53 gene therapy (Advexin) in a Phase 2 trial of 106 patients with recurrent SCCHN. Results: The percentage of patients with tumor responses defined by reductions in bi-dimensional tumor area by CT scans of 50%, 30%, 25%, 10% or stable disease of > 3 months were 8%, 10%, 11%, 16% and 20% respectively. The median survival for the entire population was 5.9 months while the responder populations defined by tumor decreases of 50%, 30%, 25%, 10% or stable disease > 3 months had median survivals of 40.8, 17.0, 13.7, 12.3 and 11.4 months respectively. There was a statistically significant increase in median survival for each of the responder populations compared to non-responders (p < 0.0009 for each comparison by logrank test). Statistical significance was maintained for the response definitions in landmark analyses excluding patients with survivals less than 3 and 6 months respectively. Locoregional disease control (CR + PR + SD > 3 months) was a stronger predictor of survival by Cox Proportional Hazard analysis (p = 0.0002) than conventional > 50% tumor reduction CR + PR response criteria (p = 0.005). With respect to abnormal p53 detected by immunohistochemistry (≥20% positive cells), 75% of patients (12/16) with p53+ tumors demonstrated locoregional disease control compared to only 18% (2/11) with p53− tumors p=0.0063 Fisher’s Exact Test. In addition, the median survival of patients with abnormal p53 was 11.6 months compared to only 3.5 months in patients with normal p53 (p=0.0007 Logrank Test). Conclusions: Our findings indicate that abnormal p53 is a predictive biomarker that identifies a subset of patients most likely to benefit from p53 gene therapy and that recurrent SCCHN tumor response definitions based upon smaller reductions in tumor size or the absence of progression (stable disease > 3 months) more accurately identified Advexin treated patients with increased survival than conventional response criteria. [Table: see text]
Collapse
Affiliation(s)
- J. J. Nemunaitis
- Mary Crowley Medical Research Center, Cedar Hill, TX; University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Louisville, Louisville, KY; Loyola University, Chicago, IL; Turku University, Turku, Finland; University of Maryland, Baltimore, MD; Wayne State University, Detroit, MI; Introgen Therapeutics, Houston, TX; University of Miami Sylvester Cancer Center, Miami, FL
| | - G. Clayman
- Mary Crowley Medical Research Center, Cedar Hill, TX; University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Louisville, Louisville, KY; Loyola University, Chicago, IL; Turku University, Turku, Finland; University of Maryland, Baltimore, MD; Wayne State University, Detroit, MI; Introgen Therapeutics, Houston, TX; University of Miami Sylvester Cancer Center, Miami, FL
| | - J. Hamm
- Mary Crowley Medical Research Center, Cedar Hill, TX; University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Louisville, Louisville, KY; Loyola University, Chicago, IL; Turku University, Turku, Finland; University of Maryland, Baltimore, MD; Wayne State University, Detroit, MI; Introgen Therapeutics, Houston, TX; University of Miami Sylvester Cancer Center, Miami, FL
| | - C. Bier-Laning
- Mary Crowley Medical Research Center, Cedar Hill, TX; University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Louisville, Louisville, KY; Loyola University, Chicago, IL; Turku University, Turku, Finland; University of Maryland, Baltimore, MD; Wayne State University, Detroit, MI; Introgen Therapeutics, Houston, TX; University of Miami Sylvester Cancer Center, Miami, FL
| | - H. Minn
- Mary Crowley Medical Research Center, Cedar Hill, TX; University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Louisville, Louisville, KY; Loyola University, Chicago, IL; Turku University, Turku, Finland; University of Maryland, Baltimore, MD; Wayne State University, Detroit, MI; Introgen Therapeutics, Houston, TX; University of Miami Sylvester Cancer Center, Miami, FL
| | - D. Van Echo
- Mary Crowley Medical Research Center, Cedar Hill, TX; University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Louisville, Louisville, KY; Loyola University, Chicago, IL; Turku University, Turku, Finland; University of Maryland, Baltimore, MD; Wayne State University, Detroit, MI; Introgen Therapeutics, Houston, TX; University of Miami Sylvester Cancer Center, Miami, FL
| | - G. Yoo
- Mary Crowley Medical Research Center, Cedar Hill, TX; University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Louisville, Louisville, KY; Loyola University, Chicago, IL; Turku University, Turku, Finland; University of Maryland, Baltimore, MD; Wayne State University, Detroit, MI; Introgen Therapeutics, Houston, TX; University of Miami Sylvester Cancer Center, Miami, FL
| | - K. Menander
- Mary Crowley Medical Research Center, Cedar Hill, TX; University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Louisville, Louisville, KY; Loyola University, Chicago, IL; Turku University, Turku, Finland; University of Maryland, Baltimore, MD; Wayne State University, Detroit, MI; Introgen Therapeutics, Houston, TX; University of Miami Sylvester Cancer Center, Miami, FL
| | - R. E. Sobol
- Mary Crowley Medical Research Center, Cedar Hill, TX; University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Louisville, Louisville, KY; Loyola University, Chicago, IL; Turku University, Turku, Finland; University of Maryland, Baltimore, MD; Wayne State University, Detroit, MI; Introgen Therapeutics, Houston, TX; University of Miami Sylvester Cancer Center, Miami, FL
| | - W. J. Goodwin
- Mary Crowley Medical Research Center, Cedar Hill, TX; University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Louisville, Louisville, KY; Loyola University, Chicago, IL; Turku University, Turku, Finland; University of Maryland, Baltimore, MD; Wayne State University, Detroit, MI; Introgen Therapeutics, Houston, TX; University of Miami Sylvester Cancer Center, Miami, FL
| |
Collapse
|
38
|
Chiorean EG, Dragovich T, Hamm J, Barrios CH, Gorini CF, Langmuir VK, Kroll S, Tidmarsh GT, Colowick AB, Loehrer PJ. Glufosfamide (GLU) plus gemcitabine (GEM) in pancreatic adenocarcinoma: Preliminary results of a phase 2 trial. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15005 Background: Glufosfamide is glucose linked to isophosphoramide mustard, the active metabolite of ifosfamide. Cancer cells use glucose at a higher rate than normal cells, which may lead to preferential metabolic targeting by GLU. The Phase 1 study established a GLU dose of 4500 mg/m2 for the GLU + GEM regimen. The objectives of the Phase 2 part of this study are to evaluate the safety and efficacy of GLU+GEM in pts with pancreatic adenocarcinoma. Methods: Eligible pts had metastatic and/or locally advanced pancreatic adenocarcinoma previously untreated with chemotherapy, Karnofsky Performance Status =70, creatinine clearance (CrCL) =60 mL/min and acceptable hematologic and liver function. Pts received GLU 4500 mg/m2 iv over 4 hours on Day 1 and GEM 1000 mg/m2 iv over 30 minutes on Days 1, 8 and 15 of every 28-day cycle. CT scans were obtained every 8 weeks. Primary endpoint was response rate. Results: Twenty-nine pts were enrolled. One patient with ineligible histology was excluded from efficacy analyses. The 14 male/15 female pts had a median age of 59 years. Median cycles on treatment was 4 (range 1–10+) and 9 pts completed all 6 cycles. Six of 28 (21%; 95% CI: 8- 41%) pts had a partial response (duration 1.0+ to 5.8+ months), one unconfirmed. Ten of 28 (36%) pts had stable disease (median duration 5.3 months). Median progression-free survival was 3.7 months. Six-month survival was 54% (95% CI: 38–78%). Grade 3/4 neutropenia and thrombocytopenia occurred in 21/29 (72%) and 8/29 (28%) pts. Five pts (18%) had a GLU-related serious adverse event (SAE). Two pts died due to SAE unrelated to GLU. Three pts developed renal failure; two were GLU-related with evidence of renal tubular acidosis (RTA). One pt developed GLU-related SAE of RTA without renal failure. The CrCL fell below 60 mL/min in 7 of 27 (26%) pts with CrCL =60 at baseline. Conclusions: Preliminary data indicate that GLU + GEM may benefit pts with chemotherapy naïve pancreatic adenocarcinoma. [Table: see text]
Collapse
Affiliation(s)
- E. G. Chiorean
- Indiana University Cancer Center, Indianapolis, IN; Arizona Cancer Center, Tucson, AZ; Norton Health Care, Louisville, KY; Centro de Hematologia e Oncologia, Porto Alegre, Brazil; Hospital NS Conceicao, Porto Alegre, Brazil; Threshold Pharmaceuticals, Redwood City, CA
| | - T. Dragovich
- Indiana University Cancer Center, Indianapolis, IN; Arizona Cancer Center, Tucson, AZ; Norton Health Care, Louisville, KY; Centro de Hematologia e Oncologia, Porto Alegre, Brazil; Hospital NS Conceicao, Porto Alegre, Brazil; Threshold Pharmaceuticals, Redwood City, CA
| | - J. Hamm
- Indiana University Cancer Center, Indianapolis, IN; Arizona Cancer Center, Tucson, AZ; Norton Health Care, Louisville, KY; Centro de Hematologia e Oncologia, Porto Alegre, Brazil; Hospital NS Conceicao, Porto Alegre, Brazil; Threshold Pharmaceuticals, Redwood City, CA
| | - C. H. Barrios
- Indiana University Cancer Center, Indianapolis, IN; Arizona Cancer Center, Tucson, AZ; Norton Health Care, Louisville, KY; Centro de Hematologia e Oncologia, Porto Alegre, Brazil; Hospital NS Conceicao, Porto Alegre, Brazil; Threshold Pharmaceuticals, Redwood City, CA
| | - C. F. Gorini
- Indiana University Cancer Center, Indianapolis, IN; Arizona Cancer Center, Tucson, AZ; Norton Health Care, Louisville, KY; Centro de Hematologia e Oncologia, Porto Alegre, Brazil; Hospital NS Conceicao, Porto Alegre, Brazil; Threshold Pharmaceuticals, Redwood City, CA
| | - V. K. Langmuir
- Indiana University Cancer Center, Indianapolis, IN; Arizona Cancer Center, Tucson, AZ; Norton Health Care, Louisville, KY; Centro de Hematologia e Oncologia, Porto Alegre, Brazil; Hospital NS Conceicao, Porto Alegre, Brazil; Threshold Pharmaceuticals, Redwood City, CA
| | - S. Kroll
- Indiana University Cancer Center, Indianapolis, IN; Arizona Cancer Center, Tucson, AZ; Norton Health Care, Louisville, KY; Centro de Hematologia e Oncologia, Porto Alegre, Brazil; Hospital NS Conceicao, Porto Alegre, Brazil; Threshold Pharmaceuticals, Redwood City, CA
| | - G. T. Tidmarsh
- Indiana University Cancer Center, Indianapolis, IN; Arizona Cancer Center, Tucson, AZ; Norton Health Care, Louisville, KY; Centro de Hematologia e Oncologia, Porto Alegre, Brazil; Hospital NS Conceicao, Porto Alegre, Brazil; Threshold Pharmaceuticals, Redwood City, CA
| | - A. B. Colowick
- Indiana University Cancer Center, Indianapolis, IN; Arizona Cancer Center, Tucson, AZ; Norton Health Care, Louisville, KY; Centro de Hematologia e Oncologia, Porto Alegre, Brazil; Hospital NS Conceicao, Porto Alegre, Brazil; Threshold Pharmaceuticals, Redwood City, CA
| | - P. J. Loehrer
- Indiana University Cancer Center, Indianapolis, IN; Arizona Cancer Center, Tucson, AZ; Norton Health Care, Louisville, KY; Centro de Hematologia e Oncologia, Porto Alegre, Brazil; Hospital NS Conceicao, Porto Alegre, Brazil; Threshold Pharmaceuticals, Redwood City, CA
| |
Collapse
|
39
|
Hamm JT, Yee S, Rajendran N, Morrissey RL, Richter SJ, Misra M. Histological alterations in male A/J mice following nose-only exposure to tobacco smoke. Inhal Toxicol 2007; 19:405-18. [PMID: 17365046 DOI: 10.1080/08958370601174875] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
The incidence and multiplicity of grossly observed and microscopic lesions of the respiratory tract of A/J mice exposed nose-only to mainstream smoke (50, 200, or 400 mg total particulate matter/m3 from 2R4F cigarettes) was compared to those of filtered air controls. Animals were necropsied at the end of exposure (5 mo) or following 4 or 7 mo of recovery. Lungs were visually inspected for tumors at all necropsies and examined histopathologically at 9 and 12 mo. At 5 mo no tumors were recorded. No significant elevations in tumor incidence or multiplicity were recorded although at 9 mo multiplicity was elevated in the mid-exposure group (0.90 versus 0.55 tumors per animal for controls). At 12 mo, multiplicity was increased over the 9-mo necropsy at all exposures except 200 mg/m3; however, there were no dose-related trends in multiplicity or incidence. Histopathological alterations included hyperplasia, metaplasia, and inflammation of the nose and larynx and proliferative lesions of the lungs. At 9 mo, the multiplicity of focal lung lesions was 1.4 per animal in controls but averaged 1.0 among smoke-exposed groups. There was an inverse relation (p < .059) between smoke concentration and the percentage of hyperplastic lesions at 9 mo. At 12 mo the high-exposure group had slightly increased multiplicity of 2.3 lesions compared with 1.6 among controls, while the percentage of hyperplasic lesions was similar between groups. Nose-only inhalation of mainstream tobacco smoke resulted in chronic inflammatory changes of the respiratory tract yet failed to produce statistically significant changes in tumor incidence or multiplicity.
Collapse
Affiliation(s)
- J T Hamm
- Lorillard Tobacco Company, Greensboro, North Carolina 27420, USA.
| | | | | | | | | | | |
Collapse
|
40
|
Sánchez JM, Mellemgaard A, Perry M, Zatloukal P, Hamm J, Belani CP, Kim E, Felip E, Berton M, Johri A. Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC): A phase I/II trial. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7104] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7104 Background: Based on its activity in a wide range of tumors including those that are taxane resistant, the novel microtubule stabilizer patupilone (EPO906; epothilone B) has the potential to treat NSCLC. Fifty patients were enrolled in phase I to evaluate safety, efficacy, and optimal dose. The phase II part of this study is investigating the antitumor activity of patupilone in 53 patients with stage IIIB/IV NSCLC. Methods: Patients with histologically or cytologically confirmed unresectable, locally advanced, or metastatic NSCLC documented before 1st-line therapy without symptomatic or uncontrolled brain metastases received patupilone at a starting dose of 10.0 mg/m2 q3wk by 20-minute IV infusion. Additional inclusion criteria: age ≥18 years; WHO performance status 0–1; prior treatment with a platinum-containing regimen. Primary objective of the phase II, single-arm, 2-stage, multicenter trial: to determine activity of patupilone q3wk (overall response using modified RECIST) in NSCLC. An additional cohort with recurrent brain metastases from NSCLC is being accrued to evaluate safety, pharmacokinetics, and activity. Results: In phase I, all patients received prior treatment with platinum therapy; 28% had received taxanes and 78% nontaxanes. Patupilone dose was escalated from 6.5 to 13.0 mg/m2 q3wk. Dose-limiting toxicities occurred in 4 patients: 1 with grade 3 asthenia and 3 with grade 3 diarrhea at various dose levels. The most frequent adverse events (AEs) were diarrhea (66%), nausea (40%), vomiting (34%), paraesthesia (32%), abdominal pain (30%), and fatigue (30%). The most frequent grade 3 AE was diarrhea (14%); a grade 4 AE (asthenia) occurred in 1 patient. Overall phase I response: 5 PR, 16 SD, and 26 PD. Based on risk-benefit analyses, 10.0 mg/m2 q3wk was recommended as the phase II dose. Phase II is ongoing: 25 of 53 patients (15 men and 6 women with NSCLC; 2 men and 2 women with brain metastases) have been enrolled. Conclusions: In phase I, patupilone q3wk was safe and well tolerated, with antitumor activity in patients with advanced pretreated NSCLC. Data from phase II will be available at time of presentation. [Table: see text]
Collapse
Affiliation(s)
- J. M. Sánchez
- Hospital Germans Trias i Pujol, Barcelona, Spain; Herlev Hospital, Herlev, Denmark; Ellis Fischel Cancer Center, Columbia, MO; University Hospital Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; University of Pittsburgh Cancer Institute, Pittsburgh, PA; UT M. D. Anderson Cancer Center, Houston, TX; Vall d’Hebron University Hospital, Barcelona, Spain; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - A. Mellemgaard
- Hospital Germans Trias i Pujol, Barcelona, Spain; Herlev Hospital, Herlev, Denmark; Ellis Fischel Cancer Center, Columbia, MO; University Hospital Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; University of Pittsburgh Cancer Institute, Pittsburgh, PA; UT M. D. Anderson Cancer Center, Houston, TX; Vall d’Hebron University Hospital, Barcelona, Spain; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - M. Perry
- Hospital Germans Trias i Pujol, Barcelona, Spain; Herlev Hospital, Herlev, Denmark; Ellis Fischel Cancer Center, Columbia, MO; University Hospital Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; University of Pittsburgh Cancer Institute, Pittsburgh, PA; UT M. D. Anderson Cancer Center, Houston, TX; Vall d’Hebron University Hospital, Barcelona, Spain; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - P. Zatloukal
- Hospital Germans Trias i Pujol, Barcelona, Spain; Herlev Hospital, Herlev, Denmark; Ellis Fischel Cancer Center, Columbia, MO; University Hospital Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; University of Pittsburgh Cancer Institute, Pittsburgh, PA; UT M. D. Anderson Cancer Center, Houston, TX; Vall d’Hebron University Hospital, Barcelona, Spain; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - J. Hamm
- Hospital Germans Trias i Pujol, Barcelona, Spain; Herlev Hospital, Herlev, Denmark; Ellis Fischel Cancer Center, Columbia, MO; University Hospital Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; University of Pittsburgh Cancer Institute, Pittsburgh, PA; UT M. D. Anderson Cancer Center, Houston, TX; Vall d’Hebron University Hospital, Barcelona, Spain; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - C. P. Belani
- Hospital Germans Trias i Pujol, Barcelona, Spain; Herlev Hospital, Herlev, Denmark; Ellis Fischel Cancer Center, Columbia, MO; University Hospital Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; University of Pittsburgh Cancer Institute, Pittsburgh, PA; UT M. D. Anderson Cancer Center, Houston, TX; Vall d’Hebron University Hospital, Barcelona, Spain; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - E. Kim
- Hospital Germans Trias i Pujol, Barcelona, Spain; Herlev Hospital, Herlev, Denmark; Ellis Fischel Cancer Center, Columbia, MO; University Hospital Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; University of Pittsburgh Cancer Institute, Pittsburgh, PA; UT M. D. Anderson Cancer Center, Houston, TX; Vall d’Hebron University Hospital, Barcelona, Spain; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - E. Felip
- Hospital Germans Trias i Pujol, Barcelona, Spain; Herlev Hospital, Herlev, Denmark; Ellis Fischel Cancer Center, Columbia, MO; University Hospital Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; University of Pittsburgh Cancer Institute, Pittsburgh, PA; UT M. D. Anderson Cancer Center, Houston, TX; Vall d’Hebron University Hospital, Barcelona, Spain; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - M. Berton
- Hospital Germans Trias i Pujol, Barcelona, Spain; Herlev Hospital, Herlev, Denmark; Ellis Fischel Cancer Center, Columbia, MO; University Hospital Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; University of Pittsburgh Cancer Institute, Pittsburgh, PA; UT M. D. Anderson Cancer Center, Houston, TX; Vall d’Hebron University Hospital, Barcelona, Spain; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - A. Johri
- Hospital Germans Trias i Pujol, Barcelona, Spain; Herlev Hospital, Herlev, Denmark; Ellis Fischel Cancer Center, Columbia, MO; University Hospital Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; University of Pittsburgh Cancer Institute, Pittsburgh, PA; UT M. D. Anderson Cancer Center, Houston, TX; Vall d’Hebron University Hospital, Barcelona, Spain; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| |
Collapse
|
41
|
Nemunaitis J, Bier-Laning C, Clayman GL, Van Echo D, Guertin L, Hamm J, Dreicer R, Yoo GH, Minn H, Bekradda M, Sutherland W, Menander KB, Sobol RE, Goodwin J. 943. Prognostic Determinants Associated with Efficacy of Adenoviral p53 Gene Therapy in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck. Mol Ther 2006. [DOI: 10.1016/j.ymthe.2006.08.1034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
42
|
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S, Au H, Ding K, Christy-Bittel J, Parulekar W. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.1] [Citation(s) in RCA: 108] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. J. Moore
- Princess Margaret Hosp, Toronto, ON, Canada; AGITG, Melbourne, Australia; NCIC Clin Trials Group, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - D. Goldstein
- Princess Margaret Hosp, Toronto, ON, Canada; AGITG, Melbourne, Australia; NCIC Clin Trials Group, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - J. Hamm
- Princess Margaret Hosp, Toronto, ON, Canada; AGITG, Melbourne, Australia; NCIC Clin Trials Group, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - A. Figer
- Princess Margaret Hosp, Toronto, ON, Canada; AGITG, Melbourne, Australia; NCIC Clin Trials Group, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - J. Hecht
- Princess Margaret Hosp, Toronto, ON, Canada; AGITG, Melbourne, Australia; NCIC Clin Trials Group, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - S. Gallinger
- Princess Margaret Hosp, Toronto, ON, Canada; AGITG, Melbourne, Australia; NCIC Clin Trials Group, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - H. Au
- Princess Margaret Hosp, Toronto, ON, Canada; AGITG, Melbourne, Australia; NCIC Clin Trials Group, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - K. Ding
- Princess Margaret Hosp, Toronto, ON, Canada; AGITG, Melbourne, Australia; NCIC Clin Trials Group, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - J. Christy-Bittel
- Princess Margaret Hosp, Toronto, ON, Canada; AGITG, Melbourne, Australia; NCIC Clin Trials Group, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| | - W. Parulekar
- Princess Margaret Hosp, Toronto, ON, Canada; AGITG, Melbourne, Australia; NCIC Clin Trials Group, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
| |
Collapse
|
43
|
Melichar B, Tabernero J, Casado E, Bridgewater J, Hamm J, Sklenar I, Holland J, Cheung W, Zaknoen S, Johri A. Phase I dose optimization trial of patupilone in previously treated patients (pts) with advanced colon cancer (ACC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3688] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- B. Melichar
- Charles Univ Medcl Sch, Hradec Kralove, Czech Republic; Vall d’Hebron Univ Hosp, Barcelona, Spain; Royal Free and Univ Coll Medcl Sch, London, United Kingdom; Louisville Oncology, Norton Healthcare, Louisville, KY; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - J. Tabernero
- Charles Univ Medcl Sch, Hradec Kralove, Czech Republic; Vall d’Hebron Univ Hosp, Barcelona, Spain; Royal Free and Univ Coll Medcl Sch, London, United Kingdom; Louisville Oncology, Norton Healthcare, Louisville, KY; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - E. Casado
- Charles Univ Medcl Sch, Hradec Kralove, Czech Republic; Vall d’Hebron Univ Hosp, Barcelona, Spain; Royal Free and Univ Coll Medcl Sch, London, United Kingdom; Louisville Oncology, Norton Healthcare, Louisville, KY; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - J. Bridgewater
- Charles Univ Medcl Sch, Hradec Kralove, Czech Republic; Vall d’Hebron Univ Hosp, Barcelona, Spain; Royal Free and Univ Coll Medcl Sch, London, United Kingdom; Louisville Oncology, Norton Healthcare, Louisville, KY; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - J. Hamm
- Charles Univ Medcl Sch, Hradec Kralove, Czech Republic; Vall d’Hebron Univ Hosp, Barcelona, Spain; Royal Free and Univ Coll Medcl Sch, London, United Kingdom; Louisville Oncology, Norton Healthcare, Louisville, KY; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - I. Sklenar
- Charles Univ Medcl Sch, Hradec Kralove, Czech Republic; Vall d’Hebron Univ Hosp, Barcelona, Spain; Royal Free and Univ Coll Medcl Sch, London, United Kingdom; Louisville Oncology, Norton Healthcare, Louisville, KY; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - J. Holland
- Charles Univ Medcl Sch, Hradec Kralove, Czech Republic; Vall d’Hebron Univ Hosp, Barcelona, Spain; Royal Free and Univ Coll Medcl Sch, London, United Kingdom; Louisville Oncology, Norton Healthcare, Louisville, KY; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - W. Cheung
- Charles Univ Medcl Sch, Hradec Kralove, Czech Republic; Vall d’Hebron Univ Hosp, Barcelona, Spain; Royal Free and Univ Coll Medcl Sch, London, United Kingdom; Louisville Oncology, Norton Healthcare, Louisville, KY; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - S. Zaknoen
- Charles Univ Medcl Sch, Hradec Kralove, Czech Republic; Vall d’Hebron Univ Hosp, Barcelona, Spain; Royal Free and Univ Coll Medcl Sch, London, United Kingdom; Louisville Oncology, Norton Healthcare, Louisville, KY; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - A. Johri
- Charles Univ Medcl Sch, Hradec Kralove, Czech Republic; Vall d’Hebron Univ Hosp, Barcelona, Spain; Royal Free and Univ Coll Medcl Sch, London, United Kingdom; Louisville Oncology, Norton Healthcare, Louisville, KY; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| |
Collapse
|
44
|
Østerlind K, Sánchez JM, Zatloukal P, Hamm J, Belani CP, Kim E, Felip E, Johri A, Berton M, Sklenar I. Phase I/II dose escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7110] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. Østerlind
- Herlev Univ Hosp, Herlev, Denmark; Hosp Germans Trias i Pujol, Barcelona, Spain; Univ Hosp Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas MD Anderson Cancer Ctr, Houston, TX; Vall d’Hebron Univ Hosp, Barcelona, Spain; Novartis Pharmaceuticals Corp, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland
| | - J. M. Sánchez
- Herlev Univ Hosp, Herlev, Denmark; Hosp Germans Trias i Pujol, Barcelona, Spain; Univ Hosp Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas MD Anderson Cancer Ctr, Houston, TX; Vall d’Hebron Univ Hosp, Barcelona, Spain; Novartis Pharmaceuticals Corp, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland
| | - P. Zatloukal
- Herlev Univ Hosp, Herlev, Denmark; Hosp Germans Trias i Pujol, Barcelona, Spain; Univ Hosp Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas MD Anderson Cancer Ctr, Houston, TX; Vall d’Hebron Univ Hosp, Barcelona, Spain; Novartis Pharmaceuticals Corp, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland
| | - J. Hamm
- Herlev Univ Hosp, Herlev, Denmark; Hosp Germans Trias i Pujol, Barcelona, Spain; Univ Hosp Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas MD Anderson Cancer Ctr, Houston, TX; Vall d’Hebron Univ Hosp, Barcelona, Spain; Novartis Pharmaceuticals Corp, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland
| | - C. P. Belani
- Herlev Univ Hosp, Herlev, Denmark; Hosp Germans Trias i Pujol, Barcelona, Spain; Univ Hosp Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas MD Anderson Cancer Ctr, Houston, TX; Vall d’Hebron Univ Hosp, Barcelona, Spain; Novartis Pharmaceuticals Corp, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland
| | - E. Kim
- Herlev Univ Hosp, Herlev, Denmark; Hosp Germans Trias i Pujol, Barcelona, Spain; Univ Hosp Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas MD Anderson Cancer Ctr, Houston, TX; Vall d’Hebron Univ Hosp, Barcelona, Spain; Novartis Pharmaceuticals Corp, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland
| | - E. Felip
- Herlev Univ Hosp, Herlev, Denmark; Hosp Germans Trias i Pujol, Barcelona, Spain; Univ Hosp Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas MD Anderson Cancer Ctr, Houston, TX; Vall d’Hebron Univ Hosp, Barcelona, Spain; Novartis Pharmaceuticals Corp, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland
| | - A. Johri
- Herlev Univ Hosp, Herlev, Denmark; Hosp Germans Trias i Pujol, Barcelona, Spain; Univ Hosp Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas MD Anderson Cancer Ctr, Houston, TX; Vall d’Hebron Univ Hosp, Barcelona, Spain; Novartis Pharmaceuticals Corp, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland
| | - M. Berton
- Herlev Univ Hosp, Herlev, Denmark; Hosp Germans Trias i Pujol, Barcelona, Spain; Univ Hosp Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas MD Anderson Cancer Ctr, Houston, TX; Vall d’Hebron Univ Hosp, Barcelona, Spain; Novartis Pharmaceuticals Corp, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland
| | - I. Sklenar
- Herlev Univ Hosp, Herlev, Denmark; Hosp Germans Trias i Pujol, Barcelona, Spain; Univ Hosp Na Bulovce, Prague, Czech Republic; Norton Healthcare/Hospital Inc., Louisville, KY; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas MD Anderson Cancer Ctr, Houston, TX; Vall d’Hebron Univ Hosp, Barcelona, Spain; Novartis Pharmaceuticals Corp, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland
| |
Collapse
|
45
|
Ramnath N, Hamm J, Schwartz G, Holden S, Eckhardt SG, Vredenburg MR, Bernacki RJ, Lathia C, Kanter P, Creaven PJ. A phase I and pharmacokinetic study of BAY59: a novel taxane. Oncology 2004; 67:123-9. [PMID: 15539916 DOI: 10.1159/000080998] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2003] [Accepted: 02/18/2004] [Indexed: 11/19/2022]
Abstract
PURPOSE To determine the maximum tolerated dose (MTD), the dose limiting toxicities (DLT) and the pharmacokinetics of BAY59, a novel taxane given as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory solid tumors. EXPERIMENTAL DESIGN Initially, 15 patients with previously treated (median of 4 prior chemotherapy regimens) refractory cancers, but with normal marrow, hepatic and renal function were treated with BAY59 at doses of 15, 30, 50, 75 and 100 mg/m2 using a standard dose escalation design. Subsequently, 11 patients were treated, 5 at 90 mg/m2 and 6 who had had prior oxaliplatin at 75 mg/m2. RESULTS At 75 mg/m2, grade 4 neutropenia was noted in 2/6 patients, of whom 1 had grade 4 neutropenia lasting more than 5 days (DLT). At 100 mg/m2, 2/2 patients had febrile neutropenia, with 1 fatality. At 90 mg/m2, 2/5 patients had DLTs, including grade 3 neuropathy, severe lower extremity pain, dehydration and grade 4 neutropenia. The MTD was determined to be 75 mg/m2. A cohort of 6 patients, previously exposed to oxaliplatin, were enrolled at the MTD to evaluate the incidence of neurotoxicity. While DLTs (grade 3 arthralgia, grade 4 neutropenia) were noted in 3/6 patients, there was no increase in the incidence of neurotoxicity. There were no responses. Pharmacokinetics of BAY59 was linear over the doses studied, with a median terminal half-life of 21 h. CONCLUSIONS The recommended phase II dose for BAY59 is 75 mg/m2.
Collapse
Affiliation(s)
- N Ramnath
- Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Alexopoulos T, Arenton M, Barbosa RF, Barker AR, Bellantoni L, Bellavance A, Blucher E, Bock GJ, Cheu E, Childress S, Coleman R, Corcoran MD, Cox B, Erwin AR, Ford R, Glazov A, Golossanov A, Graham J, Hamm J, Hanagaki K, Hsiung YB, Huang H, Jejer V, Jensen DA, Kessler R, Kobrak HGE, Kotera K, LaDue J, Ledovskoy A, McBride PL, Monnier E, Nelson KS, Nguyen H, Niclasen R, Prasad V, Qi XR, Ramberg EJ, Ray RE, Ronquest M, Santos E, Shanahan P, Shields J, Slater W, Smith D, Solomey N, Swallow EC, Toale PA, Tschirhart R, Wah YW, Wang J, White HB, Whitmore J, Wilking M, Winstein B, Winston R, Worcester ET, Yamanaka T, Zimmerman ED. A determination of the Cabibbo-Kobayashi-Maskawa parameter |V us| using KL decays. Phys Rev Lett 2004; 93:181802. [PMID: 15525151 DOI: 10.1103/physrevlett.93.181802] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/01/2004] [Indexed: 05/24/2023]
Abstract
We present a determination of the Cabibbo-Kobayashi-Maskawa parameter |V(us)| based on new measurements of the six largest K(L) branching fractions and semileptonic form factors by the KTeV (E832) experiment at Fermilab. We find |V(us)|=0.2252+/-0.0008(KTeV)+/-0.0021(ext), where the errors are from KTeV measurements and from external sources. We also use the measured branching fractions to determine the CP violation parameter |eta(+-)|=(2.228+/-0.005(KTeV)+/-0.009(ext))x10(-3).
Collapse
|
47
|
Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm J, Hecht J, Perrou B, Griffing S, Nelson B, Novotny W. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3516] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. F. Kabbinavar
- UCLA, Los Angeles, CA; US Oncology, Newport News, VA; Florida Cancer Specialists, Fort Myers, FL; Mid-Ohio Onc/Hem, Westerville, OH; Norton Health Care, Louisville, KY; Genentech, Ince, South San Francisco, CA; Genentech, South San Francisco, CA
| | - J. Schulz
- UCLA, Los Angeles, CA; US Oncology, Newport News, VA; Florida Cancer Specialists, Fort Myers, FL; Mid-Ohio Onc/Hem, Westerville, OH; Norton Health Care, Louisville, KY; Genentech, Ince, South San Francisco, CA; Genentech, South San Francisco, CA
| | - M. McCleod
- UCLA, Los Angeles, CA; US Oncology, Newport News, VA; Florida Cancer Specialists, Fort Myers, FL; Mid-Ohio Onc/Hem, Westerville, OH; Norton Health Care, Louisville, KY; Genentech, Ince, South San Francisco, CA; Genentech, South San Francisco, CA
| | - T. Patel
- UCLA, Los Angeles, CA; US Oncology, Newport News, VA; Florida Cancer Specialists, Fort Myers, FL; Mid-Ohio Onc/Hem, Westerville, OH; Norton Health Care, Louisville, KY; Genentech, Ince, South San Francisco, CA; Genentech, South San Francisco, CA
| | - J. Hamm
- UCLA, Los Angeles, CA; US Oncology, Newport News, VA; Florida Cancer Specialists, Fort Myers, FL; Mid-Ohio Onc/Hem, Westerville, OH; Norton Health Care, Louisville, KY; Genentech, Ince, South San Francisco, CA; Genentech, South San Francisco, CA
| | - J. Hecht
- UCLA, Los Angeles, CA; US Oncology, Newport News, VA; Florida Cancer Specialists, Fort Myers, FL; Mid-Ohio Onc/Hem, Westerville, OH; Norton Health Care, Louisville, KY; Genentech, Ince, South San Francisco, CA; Genentech, South San Francisco, CA
| | - B. Perrou
- UCLA, Los Angeles, CA; US Oncology, Newport News, VA; Florida Cancer Specialists, Fort Myers, FL; Mid-Ohio Onc/Hem, Westerville, OH; Norton Health Care, Louisville, KY; Genentech, Ince, South San Francisco, CA; Genentech, South San Francisco, CA
| | - S. Griffing
- UCLA, Los Angeles, CA; US Oncology, Newport News, VA; Florida Cancer Specialists, Fort Myers, FL; Mid-Ohio Onc/Hem, Westerville, OH; Norton Health Care, Louisville, KY; Genentech, Ince, South San Francisco, CA; Genentech, South San Francisco, CA
| | - B. Nelson
- UCLA, Los Angeles, CA; US Oncology, Newport News, VA; Florida Cancer Specialists, Fort Myers, FL; Mid-Ohio Onc/Hem, Westerville, OH; Norton Health Care, Louisville, KY; Genentech, Ince, South San Francisco, CA; Genentech, South San Francisco, CA
| | - W. Novotny
- UCLA, Los Angeles, CA; US Oncology, Newport News, VA; Florida Cancer Specialists, Fort Myers, FL; Mid-Ohio Onc/Hem, Westerville, OH; Norton Health Care, Louisville, KY; Genentech, Ince, South San Francisco, CA; Genentech, South San Francisco, CA
| |
Collapse
|
48
|
Alavi-Harati A, Alexopoulos T, Arenton M, Barbosa RF, Barker AR, Barrio M, Bellantoni L, Bellavance A, Blucher E, Bock GJ, Bown C, Bright S, Cheu E, Coleman R, Corcoran MD, Cox B, Erwin AR, Escobar CO, Ford R, Glazov A, Golossanov A, Gomes RA, Gouffon P, Graham J, Hamm J, Hanagaki K, Hsiung YB, Huang H, Jejer V, Jensen DA, Kessler R, Kobrak HGE, Kotera K, LaDue J, Lai N, Ledovskoy A, McBride PL, Monnier E, Nelson KS, Nguyen H, Ping H, Prasad V, Qi XR, Quinn B, Ramberg EJ, Ray RE, Ronquest M, Santos E, Senyo K, Shanahan P, Shields J, Slater W, Smith DE, Solomey N, Swallow EC, Taegar SA, Tesarek RJ, Toale PA, Tschirhart R, Velissaris C, Wah YW, Wang J, White HB, Whitmore J, Wilking M, Winstein B, Winston R, Worcester ET, Yamanaka T, Zukanovich RF. Search for the rare decay K(L)-->pi(0)e(+)e(-). Phys Rev Lett 2004; 93:021805. [PMID: 15323902 DOI: 10.1103/physrevlett.93.021805] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/17/2003] [Indexed: 05/24/2023]
Abstract
The KTeV/E799 experiment at Fermilab has searched for the rare kaon decay K(L)-->pi(0)e(+)e(-). This mode is expected to have a significant CP violating component. The measurement of its branching ratio could support the standard model or could indicate the existence of new physics. This Letter reports new results from the 1999-2000 data set. One event is observed with an expected background at 0.99+/-0.35 events. We set a limit on the branching ratio of 3.5x10(-10) at the 90% confidence level. Combining with the previous result based on the data set taken in 1997 yields the final KTeV result: BR(K(L)-->pi(0)e(+)e(-))<2.8x10(-10) at 90% C.L.
Collapse
|
49
|
Abstract
The authors sought to determine the prevalence of marijuana use in patients with epilepsy by performing a telephone survey in a tertiary care epilepsy center. Twenty-one percent of subjects had used marijuana in the past year with the majority of active users reporting beneficial effects on seizures. Twenty-four percent of all subjects believed marijuana was an effective therapy for epilepsy. Despite limited evidence of efficacy, many patients with epilepsy believe marijuana is an effective therapy for epilepsy and are actively using it.
Collapse
Affiliation(s)
- D W Gross
- University of Alberta, Edmonton, Alberta, Canada.
| | | | | | | |
Collapse
|
50
|
Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, Hagan K, Greenberg B, Colwell B, Zee B, Tu D, Ottaway J, Humphrey R, Seymour L. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21:3296-302. [PMID: 12947065 DOI: 10.1200/jco.2003.02.098] [Citation(s) in RCA: 268] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
PURPOSE To compare the selective matrix metalloproteinase inhibitor BAY 12-9566 with the nucleoside analog gemcitabine in the treatment of advanced pancreatic cancer. METHODS Patients with advanced pancreatic adenocarcinoma who had not previously received chemotherapy were randomly assigned to receive BAY 12-9566 800 mg orally bid continuously or gemcitabine 1,000 mg/m2 administered intravenously on days 1, 8, 15, 22, 29, 36, and 43 for the first 8 weeks, and then days 1, 8, and 15 of each subsequent 28-day cycle. The primary end point was overall survival; secondary end points were progression-free survival, tumor response, quality of life, and clinical benefit. The planned sample size of the study was 350 patients. Two formal interim analyses were planned. RESULTS The study was closed to accrual after the second interim analysis on the basis of the recommendation of the National Cancer Institute of Canada Clinical Trials Group Data Safety Monitoring Committee. There were 277 patients enrolled onto the study, 138 in the BAY 12-9566 arm and 139 in the gemcitabine arm. The rates of serious toxicity were low in both arms. The median survival for the BAY 12-9566 arm and the gemcitabine arm was 3.74 months and 6.59 months, respectively (P <.001; stratified log-rank test). The median progression-free survival for the BAY 12-9566 and gemcitabine arms was 1.68 and 3.5 months, respectively (P <.001). Quality-of-life analysis also favored gemcitabine. CONCLUSION Gemcitabine is significantly superior to BAY 12-9566 in advanced pancreatic cancer.
Collapse
Affiliation(s)
- M J Moore
- Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|